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1 Introduction 
1.1 Cancer 
Cancer is one of the most deadly diseases of mankind. Even though, diseases of the 
cardiovascular system currently have a higher mortality rate, intensive research allowed 
a steady decrease of cardiovascular related mortality in the last decades. In contrast, 
only minimal success has been achieved in treating cancer 
(http://www.dkfz.de/de/krebsatlas/gesamt/mort_2.html). In the US, cancer is the leading 
cause of death in the population younger than 85 years (Jemal et al., 2010). However, it 
must be pointed out, that several cancer types (e.g. chronic myeloid leukemia) have 
undergone a therapeutic revolution, whereas the 5-year overall survival of other cancer 
types (e.g. head and neck cancer) remained almost unchanged for the last decades 
(Carvalho et al., 2005; Druker et al., 2006; Gambacorti-Passerini et al., 2011).  
 
1.2 Lung cancer 
1.2.1 Epidemiology 
With the highest incidence rate of all cancer types, lung cancer accounts for more than 
1.5 million new cases and more than 1.3 million deaths worldwide each year 
(http://globocan.iarc.fr/; data from 2008). Accordingly, lung cancer is the leading cause 
of cancer related deaths, with a five-year survival rate of only 14% 
(http://www.who.int/tobacco/research/cancer/en/). In 2008, almost 30,000 men and 
13,000 women died from lung cancer in Germany. Here, whilst the number of lung 
cancer related deaths in men has decreased during the last 20 years, lung cancer 
related mortality in women is steadily increasing since more than 50 years 
(http://www.dkfz.de/de/krebsatlas/gesamt/mort_6.html). The main reason for this 
phenomenon is thought to be the increasing number of female smokers.  
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1.2.2 Histology 
Lung cancer can be divided into two major subtypes based on histopathological 
characteristics: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) 
(Petersen, 2011).  
SCLC accounts for 15-20% of all lung cancer cases and is characterized by aggressive 
growth and small tumor cell size. SCLC arises from airway bronchioles, but 
metastasizes early into other organs. Due to its aggressive growth, SCLC is usually only 
staged into limited disease (tumor restricted to one hemithorax and regional lymph node 
metastases) and extensive disease (several spatial distributed metastases) (Gustafsson 
et al., 2008; Travis and WHO, 2004).  
NSCLC describes all types of epithelial lung cancers that are not SCLC and is divided 
into several subgroups, depending on the tissue of origin (Goldstraw et al., 2011).  
• Adenocarcinoma, the most frequent form of NSCLC, accounts for 40-50% of all 
lung cancer cases. These tumors arise from epithelial cells that form the 
glandular tissue in the periphery of the alveoles. 
• Squamous cell lung cancer, accounts for 30-35% of all lung cancer cases. 
Squamous cell carcinomas also arise from epithelial cells, but from those lining 
the main bronchus. 
• Large cell carcinoma and more poorly differentiated, rare NSCLC subtypes. 
NSCLC is staged by the TNM classification of malignant tumors. The composition of T 
(tumor size and invasiveness), N (infestation of regional lymph nodes) and M (distant 
metastasis) defines the tumor stage (stage 0 – IV) and the appropriate treatment 
(http://www.cancerstaging.org/).  
 
1.2.3 Development 
Smoking is the most important risk factor for the development of lung cancer, with 80-
90% of all lung cancers being caused by tobacco smoke exposure (Khuder, 2001). 
Especially the development of squamous and small cell lung cancer is highly correlated 
with this risk factor. One likely reason for this is that these two lung cancer subtypes 
arise from areas in the lung highly exposed to inhaled air. Even though, smoking is the 
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most important risk factor for lung cancer, about 20% of adenocarcinomas develop in 
never-smoking patients. Thus, even in never smokers, lung cancer is the seventh 
leading cause of cancer death worldwide. Interestingly, these tumors use different 
survival signaling pathways as opposed to smoking induced tumors (Sun et al., 2007). 
In addition to cigarette smoke, other known carcinogens by inhalation are asbestos and 
Radon. If cells in the lung are exposed to higher doses of these carcinogens, somatic 
mutations develop. Most of these mutations can be repaired by the endogenous repair 
mechanisms of the cell. However, if the mutation load is too high, or if the repair 
mechanisms do not work properly, these mutations can persist and accumulate over 
time. Eventually, tumor suppressor genes or oncogenes are mutated, which can affect 
the behavior of the cell (as it will be discussed further below) and lead to pre-invasive 
lesions, invasive lesions and finally metastases (Braithwaite and Rabbitts, 1999; 
Brambilla and Gazdar, 2009; Herbst et al., 2008; Knudson, 1971; Noguchi, 2010). For 
such a development in the lung, non-
transformed bronchial cells need to 
gain several capabilities to allow the 
development and maintenance of an 
uncontrolled growing tumor. In 2000, 
Douglas Hanahan and Robert 
Weinberg identified six essential 
alterations in cell physiology that 
collectively dictate malignant growth: 
“self-sufficiency in growth signals, 
insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of 
programmed cell death (apoptosis), 
limitless replicative potential, sustained 
angiogenesis, and tissue invasion and 
metastasis” (Figure 1) (Hanahan and 
Weinberg, 2000). In 2011, an update 
was published, including two emerging 
Figure 1 Set of capabilities a cancer cells needs for a 
completely transformed phenotype as suggested by 
Hanahan and Weinberg (Hanahan and Weinberg, 
2000). 
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hallmarks, reprogramming of energy metabolism and evading immune destruction, as 
well as two enabling characteristics of tumor cells, namely genome instability and tumor 
promoting inflammation (Hanahan and Weinberg, 2011). This introduction will mainly 
focus on the first six hallmarks of cancer, which describe the most fundamental 
capabilities a cancer cell needs to acquire in order to develop a transformed phenotype.   
1.2.3.1 Evading apoptosis 
In the development of the human body, apoptosis is an essential mechanism to form 
tissues and organs (e.g. finger formation) and to sustain organ functionality (e.g. colon 
epithelium, T- and B-cell development etc.) (Alberts, 2002). However, apoptosis is also 
an important mechanism to dispose irreversibly damaged cells and can be triggered 
from external signals (e.g. by activation of death receptors of natural killer cells) or from 
internal signals (e.g. after extensive DNA damage). To prevent uncontrolled apoptosis, 
pro-apoptotic and anti-apoptotic proteins are tightly balanced in the normal cell. In case 
of an irreparable DNA damage, this balance shifts toward the pro-apoptotic proteins and 
thereby induces apoptosis. One of the major sentinels of the stress response is the 
tumor suppressor gene TP53. Usually locked in an inactive state in the cytoplasm, p53 
becomes active upon DNA damage, hypoxia or other stress conditions. Depending on 
the level of DNA damage, p53 will activate the transcription of genes involved in repair 
mechanisms (if the damage can be fixed), or induce apoptosis (if the DNA damage is 
too severe to be repaired) (Kruse and Gu, 2009). 
In tumor cells however, the balance of pro- and anti-apoptotic proteins is shifted towards 
the anti-apoptotic proteins, preventing apoptosis even in cells with a high load of DNA 
damage. This is often achieved by a loss of function of p53, frequently due to a mutation 
of the gene making TP53 the most frequently mutated gene in cancer (IARC TP53 
database). In fact, 50% - 70% of NSCLC and 75% - 93% of all SCLC tumors are 
mutated in this gene, highlighting its importance in preventing the development of lung 
cancer (Herbst et al., 2008; Peifer et al., under review; Travis and WHO, 2004). Thus, 
even though the stress response of a damaged bronchial cell would trigger cell death, 
the transformed cells do not die, accomplishing the first step to become a cancer cell 
(Weinberg, 2007).  
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1.2.3.2 Self-sufficiency in growth signals 
A cancer cell requires sustained chronic proliferation to form a tumor. Usually, the 
growth of a healthy cell is carefully controlled by growth factors secreted by neighboring 
cells or other tissues in the human body. After secretion, these growth factors can 
stimulate specific receptors on the surface or within cells. Ligand binding activates the 
respective receptor, triggering a cellular response specific for this growth factor (Henson 
and Gibson, 2006). One of the best-studied pro-proliferative pathways is the epidermal 
growth factor receptor (EGFR) pathway, which is activated after ligand binding to this 
cell surface receptor (Greulich et al., 2005; Henson and Gibson, 2006; Sharma et al., 
2007). Lung adenocarcinoma cells often take advantage of this growth promoting 
signaling pathway by (i) uncontrolled secretion of EGFR ligands or (ii) acquiring 
mutations in the EGF receptor itself. In both cases the result is an uncontrolled 
activation of EGFR and therefore, the constitutive activation of the downstream 
signaling pathway (Brambilla and Gazdar, 2009; Gazdar and Minna, 2008; Greulich et 
al., 2005; Paez et al., 2004; Sporn and Todaro, 1980). In addition to deregulated EGFR 
signaling, mutations in KRAS are found in up to 40% of all adenocarcinomas of the lung, 
but are rare in other forms of NSCLC and SCLC (Herbst et al., 2008; Travis and WHO, 
2004). Furthermore, growth-promoting mutations in the MAPK pathway, in the PI3K 
pathway as well as in other receptor tyrosine kinases have been described in 
adenocarcinomas (Ding et al., 2008; Engelman, 2007). In contrast, only a limited 
number of such activating mutations has been described for squamous cell carcinoma, 
with almost no known growth promoting mutations in SCLC (Bass et al., 2009; Peifer et 
al., under review; Travis and WHO, 2004; Weiss et al., 2010) 
Several additional mechanisms have been described that allow tumor cells to increase 
the pro-proliferative signaling, without an activating mutation of an oncogene. Examples 
for such mechanisms are the loss of PTEN leading to the activation of the PI3K pathway 
and a negative feedback mechanism that induces PI3K pathway activation after 
pharmacological mTOR inhibition (Sos et al., 2009b; Sudarsanam and Johnson, 2010; 
Yuan and Cantley, 2008).   
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1.2.3.3 Insensitivity to anti-growth signals  
As mentioned above, the growth of cells within a tissue is tightly controlled. In contrast 
to constantly proliferating cells as in the gut or in the skin, most cells in the human body 
do not proliferate after the tissue they form has developed. These cells are kept in a 
quiescent (G0) state by anti-growth signals, until external growth signals release the cell 
from these restraints. This process is controlled by tumor suppressor proteins, which 
negatively regulate cellular proliferation. Several tumor suppressor genes with different 
mechanisms of controlling proliferation have been described. One example is the 
retinoblastoma protein 1 (RB1), which is activated by many known external anti-growth 
signals, promoting its interaction with several transcription factors, and consequently 
altering the expression of genes that promote transition from the G0 or G1 into the S-
phase of the cell cycle (Alberts, 2002; Weinberg, 2007). To evade the anti-growth 
signals mediated by RB1 activation, lung cancer cells universally inactivate this protein. 
In SCLC, RB1 is most often inactivated by deletions or loss of function mutations. These 
are frequently accompanied by deletion of the remaining wild-type allele (LOH, loss of 
heterozygosity), making loss of RB1 a hallmark feature of SCLC. In NSCLC, the RB1 
pathway is often inactivated by inhibitory mechanisms upstream of RB1 (Knudson, 
1971; Nevins, 2001; Peifer et al., under review; Travis and WHO, 2004). This can for 
example be achieved by loss of p16INK4 (CDKN2A) activity, or the overexpression of 
cyclin D1 (Brambilla and Gazdar, 2009; Ding et al., 2008; Travis and WHO, 2004). 
CDKN2A is mutated in almost 40% of all lung adenocarcinomas and encodes for the 
RB1 and p53 regulators p16INK4 and p14ARF (Brambilla and Gazdar, 2009; Ding et al., 
2008). 
1.2.3.4 Sustained angiogenesis 
If cancer cells start to proliferate in the human body, they form a tumor mass that 
consists mainly of transformed cells. As soon as the tumor mass reaches the size of 
approximately 0.2 mm3, the diffusion of oxygen and nutrients is not sufficient to supply 
the inner cells of the tumor. Therefore, new blood vessels need to pervade the tumor 
mass to ensure a steady nutrient and oxygen supply, a process called tumor-associated 
neovasculature. The best-studied growth factor to increase vascular permeability and to 
induce the sprouting of new blood vessels is the vascular endothelia growth factor 
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(VEGF) (Senger et al., 1983; Weinberg, 2007). VEGF is often secreted by cancer cells, 
which is thought to secure the oxygen supply of the tumor by increasing the number 
blood vessels penetrating the tumor mass. In lung cancer, high levels of VEGF were 
especially observed in non-small cell lung cancer, correlating with neovascularization 
within the tumor (Stefanou et al., 2004; Yuan et al., 2000). Furthermore, in NSCLC, 
VEGF expression has been shown to correlate with poor prognosis, arguing for an 
important role of VEGF in lung cancer progression (Bremnes et al., 2006; Herbst et al., 
2005). However, it has been shown, that even though an inhibition of VEGF signaling 
decreases the number of blood vessels within the tumor and the size of the primary 
tumor itself, the aggressiveness of tumor cells to metastasize increases dramatically 
(Paez-Ribes et al., 2009). Recent findings indicate, that a combined inhibition of VEGF 
and MET signaling can prevent this increase in invasiveness, highlighting the 
importance to understand biological processes before being able to target them for the 
treatment of cancer (Sennino et al., 2012; Vecchiarelli-Federico et al., 2010) 
1.2.3.5 Limitless replicative potential 
Most cells in the human body have only a limited replication capacity. The number of 
possible cell divisions is defined by the length of the telomeres, which are repetitive 
sequences at the end of each chromosome. Each cell division leads to a loss of 
approximately 100 bp of telomere DNA, thus allowing the cell only a limited number of 
cell divisions (Counter et al., 1992). Critical shortening of the telomeres induces a DNA 
damage response, eventually initiating cellular senescence (losing the ability to divide) 
or apoptosis (Brambilla and Gazdar, 2009). To allow stem cells (cells with an unlimited 
replication potential; e.g. in the skin) an inexhaustible capability of cell divisions, the 
gene TERT is expressed. This gene encodes the catalytic subunit of the telomerase 
complex, which elongates telomeres at the end of each G2 phase and thereby prevents 
telomere shortening. Lung cancer cells often show an increased expression of TERT to 
prevent the telomere dependent termination of replication. A high telomerase activity 
has been observed in NSCLC and SCLC, allowing the tumor cells to divide indefinitely 
(Chen and Chen, 2011; Greider and Blackburn, 1985; Saretzki et al., 2002; Weinberg, 
2007; Zhang et al., 2000).  
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1.2.3.6 Tissue invasion and metastasis 
The three-dimensional structure of a tissue is maintained by direct interactions between 
the cells through adhesion proteins such as cadherins and integrins. These adhesion 
proteins also provide pro-survival and anti-proliferation signals, leading to the induction 
of apoptosis if a cell detaches from this interaction network (a process called anoikis). In 
the later stages of lung cancer development, tumor cells no longer depend on survival 
signals provided by neighboring cells. Due to the loss of E-cadherin expression, a key 
cell-cell adhesion molecule, these cells can leave the primary tumor mass and migrate, 
via the blood stream or the lymph vessel system, to any other site in the human body 
(Bremnes et al., 2002; Derksen et al., 2006; Kase et al., 2000). After the invasion of a 
distant organ, a metastasis arises, explaining the poor survival of lung cancer patients, 
whose tumors express low levels of E-cadherin (Bremnes et al., 2002; Fidler, 2003; 
Kase et al., 2000; Noguchi, 2010). 
1.2.4 Treatment of lung cancer 
Chemotherapy is the standard therapy for lung cancer, which, unfortunately, rarely 
cures the disease. Small cell lung cancer initially responds very well to chemotherapy 
and radiation treatment. However, almost all of these tumors develop resistance to this 
treatment and eventually relapse. The aggressive phenotype and the early appearance 
of resistance in SCLC are reflected in the five-year overall survival rate of less than 5% 
(Gustafsson et al., 2008). In general, compared to SCLC, NSCLC is relatively 
insensitive to chemotherapy. Instead, standard therapy for localized NSCLC includes 
surgical resection followed by chemotherapy. Unfortunately, NSCLC in advanced 
stages (as is the case for most diagnosed lung cancers) is already a systemic disease 
and cannot be surgically resected. Therefore, advanced stages are mainly treated by 
chemotherapy and/or radiation, although the response to these treatments is very poor 
(http://www.cancer.gov/cancertopics/types/lung). Depending on the stage of the tumor, 
five-year survival rates for NSCLC vary from almost 50% for stage IA to 1% for stage IV 
(www.cancer.org).  
In addition to the relatively unspecific treatment options of chemotherapy and radiation, 
researchers have identified several genetic markers (mainly mutations) that allow a 
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more specific treatment of certain lung cancers. These mutations often induce the 
transformed state in the first place, therefore, being good markers to distinguish cancer 
cells from non-transformed healthy cells. In addition, several of these mutations also 
lead to a dependency (“oncogene addiction”) of the tumor cell to the mutation-activated 
growth signal. Thus, inhibition of these growth signals (e.g. by a drug) induces 
apoptosis mainly in mutated cells. Compared to chemotherapy and radiation, side 
effects of these targeted therapies are less pronounced (Kwak et al., 2010; Mok et al., 
2009). Unfortunately, even though a broad range of mutations has been identified so far, 
many transforming mutations are still unknown or cannot be specifically targeted by 
drugs (yet) (Herbst et al., 2008; Pao et al., 2005b). 
 
1.3 Oncogenes and tumor suppressor genes 
In 1911, Peyton Rous published a work describing a sarcoma-inducing agent found in 
chicken sarcomas. This agent was small (passing a fine-pore filter), was capable to 
multiply within the chicken tissue and induced tumors on predictable timetables (Rous, 
1983). This agent later became known as the Rous sarcoma virus (RSV). The discovery 
of Peyton Rous allowed researchers to describe several cancer-causing viruses that 
were able to transform normal cells in the culture dish. More than 60 years later, 
Michael Bishop and Harold Varmus used a DNA probe to tag the transformation-
associated viral gene in the genome of transformed cells. Surprisingly, even non-
transformed chicken cells were marked by this DNA probe, with two copies per genome. 
This discovery revolutionized the thinking about cancer by showing that endogenous 
genes (proto-oncogenes) can play a role in tumor formation. Further characterization of 
the transforming viral oncogene v-src and its similar human c-src counterpart illustrated 
that minimal differences in DNA sequence are capable to convert a proto-oncogene to 
an transformation promoting oncogene. These discoveries paved the way for the 
characterization of several cellular proto-oncogenes and oncogenes in the human 
genome (Bishop, 1990; Varmus, 1990). After mutation of these genes, the resulting 
proteins gain pro-survival activity that is independent of external control and thus can 
induce the transformation of the cell. In addition, most oncogenes elicit an “oncogene 
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addicted” phenotype, describing the addiction of the tumor cell to constant activation of 
the respective mutated protein or signaling pathway. The most frequently mutated 
oncogenes in lung cancer are EGFR, KRAS, PIK3CA, ERBB2 and BRAF, as well as 
translocations of ALK, RET and ROS1 and amplifications of MET and PDGFR 
(Brambilla and Gazdar, 2009; Herbst et al., 2008; Sharma et al., 2010; Takeuchi et al., 
2012).   
In comparison to the activated oncogenes that act in a dominant fashion, tumor 
suppressor genes act as negative regulators and thereby in a recessive manner. The 
first tumor suppressor gene that has been discovered was the retinoblastoma gene 
(RB1), which, if mutated in both alleles, leads to the formation of retinoblastoma, a 
childhood eye tumor. This tumor type appears in two forms. Children without a family 
history of retinoblastoma usually develop a sporadic tumor in only one eye (unilateral). 
Children with a family history of retinoblastoma however, often develop tumors in both 
eyes (bilateral). In 1971, Alfred Knudsen studied the kinetics of sporadic and familial 
retinoblastoma and concluded, that the rate of sporadic tumors was consistent with two 
random genetic events, whereas the rate of familial retinoblastoma tumor development 
seemed to require only one single random genetic event (Knudson, 1971). Thus, 
children with familial retinoblastoma already carried one mutated allele of the RB1 gene 
after birth, requiring only one additional mutation in the other allele for a complete loss 
of function of this gene. In sporadic retinoblastoma however, loss of functions for both 
wild-type alleles is needed for the tumor to develop. Indeed, tumor suppressor genes 
are either mutated in both alleles of the genome or, if only one allele is mutated, the 
non-mutated allele is often lost by LOH. As stated above, the RB1 pathway is also 
universally inactivated in lung cancer, allowing the tumor cells to escape the RB1 
mediated cell cycle control. 
1.3.1  Somatic mutations 
Mutations describe genetic changes in the genomic DNA of a cell. These changes can 
be single nucleotide substitutions (point mutations), nucleotide insertions or deletions, 
gene fusions or genomic amplifications/deletions. If a mutation is a germ-line mutation 
(i.e. the mutation occurred in the germ cells), it can be detected in every cell of the 
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organism if transmitted to offspring. A somatic mutation however develops only in 
somatic cells, and is therefore not transmitted to offspring.  
Several germ-line mutations have been described that increase the risk of tumor 
development during the lifespan of the individual. These mutations often occur in tumor 
suppressor genes or weak oncogenes that, even though mutated, allow the 
development of the organism. Other mutations might accelerate the accumulation of 
novel mutations (e.g. by loss of function in DNA-repair pathways) and thereby increase 
the risk of future cancer development (Birch et al., 2001; Ford et al., 1998; Linehan et al., 
2007; Marx, 2005; Mosse et al., 2008; Thompson et al., 2005; Vasen et al., 2001).  
Most cancers arise from somatic mutations, which can be defined as somatic by 
sequencing the tumor cells and non-transformed cells (e.g. from the skin) (Ding et al., 
2008). Due to technological advances in sequencing techniques in the last decades, it is 
today possible to gain a comprehensive view on the genomic aberrations of cancer 
cells. The genomic analysis of thousands of tumors and non-transformed tissues 
uncovered a huge number of somatic changes in the genome of tumor cells, which, 
depending on tumor subtype, can vary dramatically. In general, the more the tumor cells 
have been exposed to carcinogens during their lifespan, the more mutations are found 
(Beroukhim et al., 2010; Campbell et al., 2010; Feuk et al., 2006; Peifer et al., under 
review; Pleasance et al., 2010). In total, several thousand mutations can be found in a 
tumor genome, with, depending on tumor type, only 12 to 228 causing any functional 
changes in proteins. If mutations outside the exome also lead to functional changes in 
DNA or RNA structure and thereby cause cancer is currently unknown.  
Most mutations that have been found in oncogenes are restricted to certain areas or 
domains within the gene. A reason for this observation in kinases seems to be, that only 
very few amino acid changes are capable to increase the activity of the evolutionary 
optimized kinase. Thus, the plasticity of a kinase does not tolerate many amino acid 
changes without a loss in kinase activity. Tumor suppressor gene mutations however 
often harbor nonsense mutation (stop-codon) mutations, frame-shift mutations, or 
mutations that are distributed across several domains essential for a proper functioning 
of the protein (Harris, 1993). In either case, these mutations lead to a loss of function of 
the tumor suppressor. In support of this notion, frame-shift or nonsense mutations are 
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almost exclusively found in tumor suppressor genes (Dalgliesh et al., 2010; Ding et al., 
2008; Varela et al., 2011; Yeang et al., 2008).  
Although, up to 228 amino acid changing mutations are found in certain tumor types, 
only a few (known as “driver” mutations) lead to the transformed phenotype of the tumor 
cells. These “driver mutations” often occur in oncogenes and lead to an increase in 
protein activity that is independent of external control mechanisms. An indication for the 
transformation capacity of a single mutation is (i) the frequency of this mutation in 
tumors and (ii) in vitro transformation assays in the laboratory that show the 
transformation capacity of this mutation in an eukaryotic cell (Forbes et al., 2011; 
Greulich et al., 2005; Yan et al., 2009). Today, a large set of “driver mutations” across 
different tumor types has already been described. Careful analysis of the signaling 
pathways that are activated by these mutations however revealed only a limited number 
of pathways that seem to induce cellular transformation (Ding et al., 2008; TCGA, 2008).  
1.3.2  Fusion genes 
In contrast to kinases that are activated by point mutations (e.g. the L858R mutation in 
EGFR), kinases of fusion proteins are often constantly activated by a permanent 
homodimerization, mediated by the N-terminal fusion partner (Golub et al., 1996; 
McWhirter et al., 1993; Soda et al., 2007). Genomic rearrangements that lead to gene 
fusions can create novel proteins with new/enhanced activities. Here, the first part on 
the fusion gene consists of a varying number of exons from gene A and the second part 
of a varying number of exons from gene B. The size oft the resulting protein can vary 
from small (RAF1-ESRP1, approx. 30 kDa) to very big (BCR-ABL, 210 kDa) (Evans et 
al., 1987; Palanisamy et al., 2010). If the breakpoint leads to a frame-shift, the 
functionality of gene B is often compromised as it is after copy number loss or nonsense 
and frame-shift mutations. If the gene fusion is “in frame”, the emerging fusion protein 
can develop new abilities that are nonexistent in both (wild type) fusion partners.  
Examples for such “in frame” fusions are translocations of ALK. ALK has been first 
discovered fused to nucleophosmin (NPM1) in anaplastic large-cell lymphoma, giving 
this gene its name (anaplastic lymphoma kinase) (Morris et al., 1994). ALK belongs to 
the insulin receptor superfamily and, in its native form, is thought to play a role in the 
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development and functionality of the nervous system (Palmer et al., 2009). In 2007, the 
first oncogenic fusion gene in lung cancer has been described, a translocation involving 
ALK (Soda et al., 2007). In lung cancer however the predominant 5’-partner of ALK-
fusions involves echinoderm microtubule associated protein like-4 (EML4), with few 
reported cases that expressed ALK being fused to kinesin family member 5B (KIF5b), 
kinesin light chain 1 (KLC1) or the TRK-fused gene (TFG), which has also been 
described in anaplastic large-cell lymphoma (Hernandez et al., 1999; Takeuchi et al., 
2009; Togashi et al., 2012). About 2-7% of lung adenocarcinomas harbor an EML4-ALK 
gene fusion, one of the first fusion genes discovered in solid tumors (Kwak et al., 2010; 
Soda et al., 2007). Depending on the proportion of EML4 that is fused to the kinase 
domain of ALK, different variants develop, with variant one (v1, EML4 exon 13 being 
fused to ALK exon 20), variant two (v2, EML4 exon 20 being fused to ALK exon 20) and 
variants three a/b (v3a/v3b, EML4 exon 6 being fused to ALK exon 20) being the most 
frequent fusion variants (Figure 2). EML4-ALK variant 1 is found in 33%, EML4-ALK 
variant 2 in 10% and EML4-ALK v3a/v3b in 29% of all EML4-ALK positive cases (Choi 
et al., 2008; Sasaki et al., 2010b). All EML4-ALK variants harbor the coiled-coiled 
domain of EML4, which is essential for the homodimerization and thus the constitutive 
activation of the ALK kinase domain. In addition, almost all variants harbor exons 20-29 
Figure 2 Schematic representation of different EML4-ALK variants and other ALK fusions that 
have been found in lung tumors. Domains essential for oncogenic signaling are indicated in dark 
gray. The nomenclature on the left refers to the respective exon in EML4 translocated to the 
indicated exon in ALK. Figure from (Sasaki et al., 2010b). 
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of ALK, which encode the ALK tyrosine kinase domain (Doebele et al., 2012; Soda et 
al., 2007).  
All known EML4-ALK fusions are oncogenic in vitro and/or in vivo and transformed cells 
expressing this fusion gene are sensitive to ALK kinase inhibitors (McDermott et al., 
2008; Soda et al., 2007; Soda et al., 2008; Takeuchi et al., 2008). In addition to these 
ALK fusions, ALK translocations have also been described for inflammatory 
myofibroblastic tumors, diffuse large B-cell lymphoma and, more rarely, in breast, colon 
and renal cell carcinoma (Chiarle et al., 2008; Gleason and Hornick, 2008; Lin et al., 
2009; Sugawara et al., 2012). Furthermore, ALK has also been described to be 
deregulated by point mutations in neuroblastoma and, rarely, in thyroid cancer (Chen et 
al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008; 
Murugan and Xing, 2011; Palmer et al., 2009). These ALK mutations have been 
described to be kinase activating, and it is hoped that these ALK mutated tumors can 
(as EML4-ALK expressing lung tumors) be effectively treated with ALK kinase inhibitors. 
 
1.4 Kinases  
Kinases are a class of enzymes that, after activation, regulate many biological 
processes by transferring a phosphate group from adenosine-5'-triphosphate (ATP) to a 
hydroxyl group of serine, threonine or tyrosine on the substrate. The bulky and charged 
phosphate group alters the properties of the substrate protein by changing the 
conformation, charge, molecular weight and association capacity of the protein. The 
transfer of the phosphate group takes place in a highly conserved catalytic subunit of 
the protein that binds ATP and catalyzes the transfer of the terminal γ-phosphate to a 
kinase specific substrate. This catalytic subunit is located in a deep cleft between the N-
lobe and the C-lobe of the kinase, a region defined by a conserved helix-C, a conserved 
sequence motif (GXGXXG) containing glycine-rich loop and an activation loop with the 
DFG (Asp-Phe-Gly) motif. In most kinases, a lysine residue buried in the interlobe cleft 
(K72 in Figure 3) and a glutamic acid in helix-C (E91 in Figure 3) arrange the ATP 
molecule for catalysis (Figure 3) (Huse and Kuriyan, 2002). 
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Depending on the substrate residue that is 
phosphorylated, kinases are subdivided in tyrosine 
kinases and serine/threonine kinases. Tyrosine kinases 
can be further subdivided into receptor tyrosine kinases 
and cytoplasmic kinases. Receptor tyrosine kinases 
transfer external signals into the cell, whereas 
cytoplasmatic kinases transmit and enhance signals 
within the cell.  
Receptor tyrosine kinases (RTKs) are transmembrane 
proteins that bind specific ligands on the extracellular 
end of the receptor and transmit the signal through the 
plasmamembrane into the cytoplasm of the cell (e.g. 
EGFR). In the case of EGFR, the RTK can be found as 
inactive monomer or dimer (Figure 4 left). Ligand binding to specific extracellular 
ligand-binding domains induces changes in the three-dimensional structure of the RTK, 
leading to the formation of an asymmetric dimer, which is stabilized by the association 
of two juxtamembrane domains. In this asymmetric dimer, the C-lobe of one kinase 
domain binds to the N-lobe of the other kinase domain, thereby stabilizing the active 
conformation of this kinase (Figure 4 middle) (Endres et al., 2011; Schlessinger, 2002). 
The activation of this kinase is defined by an inward directed formation of the DFG-motif 
(“DFG-in”) and leads to an autophosphorylation of the C-terminus of EGFR, allowing the 
association of several Src homology 2 (SH-2) and phosphotyrosine-binding (PTB) 
domain containing downstream effector molecules (Figure 4 right). These adaptor 
proteins then activate downstream signaling cascades by triggering the assembly of 
signaling complexes with additional multidomain binding partners. The intracellular 
multi-step transduction leads to an amplification of the initial signal which eventually 
results in the stimulation of cellular proliferation (Schlessinger and Lemmon, 2003). 
Non-receptor tyrosine kinases, or cytoplasmic kinases, are intracellular kinases, 
activated by specific stimuli, which are then transmitted via substrate phosphorylation to 
proteins downstream in the signaling pathway (e.g. ABL1).  
 
Figure 3 Schematic model of 
critical components of a kinase 
domain. The activated kinase 
domain of protein kinase A 
(PKA) is shown. Figure from 
(Jura et al., 2011). 
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Mutations in tyrosine kinases have been found in many tumor genomes, with several of 
them being “driver mutations”. About 90 tyrosine kinases have been described in the 
human genome, with the most studied tyrosine kinases including the epidermal growth 
factor receptor (EGFR) and the Abelson tyrosine-protein kinase (ABL1) (Chmielecki et 
al., 2010; Druker et al., 2001; Lynch et al., 2004; Paez et al., 2004). In the case of 
EGFR, the most frequent mutations are deletions of amino acids 746-750 in exon 19 
and point mutations in exon 21. Both mutations lead to a constant kinase activation, 
independently of ligand binding (Greulich et al., 2005; Yuza et al., 2007). Oncogenic 
activation of the Abl kinase is, in contrast to EGFR, mainly achieved by a translocation 
between chromosome 9 and 22 leading to the well-known “Philadelphia chromosome” 
(described in 1960 by Peter Nowell and David Hungerford in Philadelphia, USA). The 
Philadelphia chromosome is found in 95% of all chronic myelogenous leukemias (CML) 
as well as (to a lower extent) in acute lymphoblastic leukemia and acute myelogenous 
Figure 4 Schematic model of EGF receptor activation. After binding to EGF, the kinase domains of 
two EGFR proteins form an asymmetric dimer, which allows the autophosphorylation of the kinase 
(middle). Phosphorylated tyrosine residues at the C-terminal of the receptor serve as adaptor sites for 
several downstream signaling proteins (right). Figure from (Endres et al., 2011).   
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leukemias (Kurzrock et al., 1987; Nowell and Hungerford, 1960). This translocation 
leads to a constant homodimerization of the fusion protein, which disrupts the 
autoinhibited conformation of Abl and thereby leads to a continuous activation of the 
tyrosine kinase (McWhirter et al., 1993; Smith et al., 2003). In EML4-ALK, the kinase 
domain of ALK becomes independent of ligand activation by a constant 
homodimerization via the coiled-coiled domain of EML4 (Mano, 2008; Soda et al., 2007).  
In addition to these kinases that are activated by point mutation or translocation, some 
RTKs are known to be transforming only by overexpression of the protein (e.g. ERBB2 
and MET) (Di Fiore et al., 1987; Engelman et al., 2007). Here, the higher abundance of 
the RTK on the cell surface is sufficient to induce dimerization and kinase activation.  
1.4.1  Kinase inhibitors 
Kinase inhibitors are small molecules, peptides or antibodies that inhibit the catalytic 
activity of a kinase. Small molecule kinase inhibitors are subdivided into three different 
classes, depending on the binding mode of the inhibitor to the kinase. Type-I inhibitors 
compete with ATP to bind to the ATP-binding pocket within the kinase domain. Most of 
these compounds bind to the kinase by forming hydrogen bonds with the hinge region 
and by hydrophobic interactions, which are usually carried out by the adenine ring of 
ATP. If the affinity of the small molecule to the kinase is higher than that of ATP, the 
molecule prevents the binding of 
ATP to the kinase and thereby 
the transfer of the phosphate 
group to the substrate. Thus, 
the activation of the signaling 
pathway is inhibited. Type-II 
inhibitors also bind to the ATP 
binding pocket by forming 
hydrogen bonds with the hinge 
region, but extent into a 
hydrophobic pocket, which 
emerges in a “DFG-out” 
Figure 5 Crystal structure (2XP2) of the ALK kinase hinge 
region is shown. On the left, ADP (black sticks) is bound to 
the kinase; on the right, the type-II inhibitor crizotinib (black 
sticks) is bound to the ALK kinase domain. PyMol file was 
generated by Christian Grütter, TU Dortmund, Germany. 
 27 
conformation and is thereby only present in the inactive kinase conformation (Figure 5). 
Thus, Type-II inhibitors can only bind to the inactive conformation of the kinase, but 
have the potential to elicit higher kinase specificity due to a lower conservation of the 
hydrophobic (“DFG-out”) pocket. Type-III inhibitors are allosteric inhibitors, which bind 
somewhere distant to the ATP-binding pocket. These inhibitors prevent the formation of 
an active kinase conformation and thereby the activation of downstream signaling 
proteins (Davis et al., 2011; Liu and Gray, 2006).  
In 2001, imatinib was the first small molecule kinase inhibitor to receive FDA approval. 
Imatinib is a type-II Abl kinase inhibitor and was developed for the treatment of BCR-
ABL expressing CML (Druker et al., 2006; Druker et al., 2001). Today, due to its “off-
target” inhibition of the RTKs KIT and PDGFR, imatinib is approved for the treatment of 
several cancer types including gastrointestinal stromal tumors and chronic eosinophilic 
leukemia (Demetri et al., 2002; Piccaluga et al., 2007).   
1.4.1.1 EGFR kinase inhibitors  
In 2004, EGFR mutations were discovered in lung tumors that responded well to the 
EGFR inhibitor gefitinib (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). Gefitinib 
and erlotinib, EGFR inhibitors with similar binding modes, are small molecules (mol. 
Mass ≈ 400 g/mol) that bind to the hinge region of the ATP-binding cleft and compete 
with ATP for binding to the active kinase domain of EGFR (Wakeling et al., 2002). As a 
result, these drugs induce apoptosis in cells that are dependent on constant EGFR 
signaling. However, EGFRwt signaling also exercises several non-oncogenic cellular 
processes. Thus, by binding to the EGFRwt receptor, gefitinib and erlotinib induce side 
effects that include skin rash and diarrhea, resulting from wild-type EGFR inhibition in 
the skin and gut, respectively. Depending on the specific mutation in EGFR, the binding 
affinity to gefitinib and other EGFR kinase inhibitors varies dramatically (Kancha et al., 
2009; Sharma et al., 2007; Soria et al., 2011). Some of these mutations develop during 
the treatment with an EGFR inhibitor and thereby induce resistance (see below). To 
overcome resistance for some of these EGFR mutations, several new EGFR inhibitors 
with different binding modes as well as novel treatment strategies have been developed 
in the last years (Regales et al., 2009; Zhou et al., 2009).  
 28 
1.4.1.2 ALK kinase inhibitors 
Pre-clinical models for EML4-ALK positive tumors have shown that these cells are 
highly sensitive to ALK kinase inhibition (Koivunen et al., 2008; McDermott et al., 2008; 
Soda et al., 2007; Soda et al., 2008). Recently, a phase I/II study in advanced, ALK 
translocation positive non-small cell lung cancer (NSCLC) demonstrated strong 
radiographic tumor shrinkage after treatment with the type-II aminopyridine ALK kinase 
inhibitor crizotinib (PF02341066) (Kwak et al., 2010). Originally developed as a MET 
inhibitor, this drug shows relatively high binding affinities to the closely related RTK 
ALK. Therefore, immediately after the discovery of EML4-ALK translocations in lung 
cancers, crizotinib was used to treat these tumors (Kwak et al., 2010; Solomon et al., 
2009; Timofeevski et al., 2009). In 2011, crizotinib was approved for the treatment of 
EML4-ALK positive lung cancer (FDA news release, August 26 2011). The impact of the 
respective fusion variant on the therapeutic efficacy of ALK inhibition is currently 
unknown (Sasaki et al., 2010b). However, recent studies of EML4-ALK positive tumors 
treated with crizotinib suggest a relatively heterogeneous response to this inhibitor (FDA 
news release, August 26 2011).  Several other ALK kinase inhibitors that vary in 
scaffold structure, potency and selectivity, have been developed in the last years 
(Milkiewicz and Ott, 2010). One of these inhibitors is TAE684, a very potent type-I ALK 
inhibitor, which is only available for pre-clinical applications (Bossi et al., 2010; Galkin et 
al., 2007).  
1.4.2  Resistance mechanisms 
In spite of the fact that targeted therapies show promising results regarding tumor 
response rates and the induction of side effects, all patients that are treated with 
targeted therapies will eventually develop resistance. Some tumors might even express 
up-front resistance mechanisms that prevent compound activity from the beginning 
(Engelman and Janne, 2008; Mok et al., 2009; Turke et al., 2010). Resistance 
mechanisms are divided into in-cis or in-trans resistance, depending on the underlying 
mechanism of resistance.  
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1.4.2.1 Resistance in-cis 
Resistance in-cis is defined by a structural change on the drug target (usually by a point 
mutation), which prevents or hinders the inhibitor to bind to its target. In BCR-ABL 
positive cells, several point mutations inducing resistance to the Abl inhibitor imatinib 
have been described. The most frequent resistance mutation leads to the amino acid 
change T315I (Shah et al., 2002). This mutation, known as the “gatekeeper” mutation, 
sterically impedes the binding of imatinib to the kinase domain and therefore allows the 
BCR-ABLT315I expressing cells to survive. The same mechanism of resistance has been 
described for EGFR mutated lung cancer, where the “gatekeeper mutation” T790M is 
hampering gefitinib binding (Kobayashi et al., 2005; Paez et al., 2004; Pao et al., 2005a; 
Zhou et al., 2009). The threonine residues BCR-ABLT315 and EGFRT790 control the 
access of kinase inhibitors to a hydrophobic pocket in a recess of the kinase ATP-
binding pocket, leading to the designation as “gatekeeper” residues. Notably, 
“gatekeeper mutations” do not interfere with the catalytic activity of the kinase, but lead 
to an increase in ATP affinity and are thereby transforming by themself (Azam et al., 
2008). This effect, as well as the steric interaction of the bulkier isoleucine or methionine 
residue with the drug, induces resistance to kinase inhibitor treatment (Figure 6) 
(Kobayashi et al., 2005; Yun et al., 2008).  
Most of the resistance mutations found in kinases either directly interfere with drug 
binding or induce a kinase conformation that impedes drug binding. However, kinase 
inhibitors with a different binding mode or inhibitors that do not interfere with the 
mutated amino acids are still capable to bind the kinase and inhibit signaling in these 
cells. Unfortunately, most Abl kinase inhibitors are not capable to overcome T315I 
induced resistance in BCR-ABL 
expressing tumors (Shah et al., 
2004). However, several recent 
pre-clinical studies suggest the 
development of successful 
targeted therapies against these 
frequent “gatekeeper mutations” 
(Chan et al., 2011; O'Hare et al., 
Figure 6 Crystal structure (PDB-code: 1M17) of erlotinib 
(black sticks) bound to EGFRwt (left) and EGFRT790M (right). 
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2009; Thomas et al., 2011; Zhou et al., 2009). In addition to new drug scaffolds with 
different binding modes, several studies suggest a combination treatment with drugs 
targeting essential downstream signaling proteins of the respective oncogenic pathway 
(Engelman and Settleman, 2008; Shimizu et al., 2012; Sos et al., 2009a). However, in 
the case of an EML4-ALK xenograft model, the combined treatment of PI3K and MEK 
inhibitors did not result in significant tumor regression (Chen et al., 2010) 
1.4.2.2 Resistance in-trans 
Resistance mechanisms in-trans are not found on the targeted protein itself. Here, 
another genetic event (i.e. mutation/fusion/amplification/overexpression of another 
gene) leads to the observed resistant phenotype. The most prominent example for in-
trans resistance are MET amplifications in EGFR mutated tumors, leading to resistance 
to EGFR inhibition. In this case, MET signaling can substitute for the EGFR signaling 
that is lost due to kinase inhibition, and thereby prevent the induction of apoptosis 
(Engelman et al., 2007; Turke et al., 2010). Other examples for in-trans resistance have 
been found in BRAFV600E mutated tumors treated with PLX4032 (a BRAF inhibitor). 
Here, resistance can be induced by the overexpression of COT or PDGFRβ and 
activating mutations in MEK1 or NRAS (Emery et al., 2009; Johannessen et al., 2010; 
Nazarian et al., 2010) 
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2 Objective of this study 
EML4-ALK positive lung cancers can be effectively treated with ALK tyrosine kinase 
inhibitors (Kwak et al., 2010). However, the response rate and the individual duration of 
response are very heterogeneous. Furthermore, acquired resistance limits the efficacy 
of ALK inhibitors, but only few resistance mutations have been described (Choi et al., 
2010; Katayama et al., 2011; Sasaki et al., 2010a; Zhang et al., 2011).  
To analyze mechanisms that influence the sensitivity to ALK kinase inhibition, three 
major questions were addressed in this study: 
1. Do different EML4-ALK variants respond differently to ALK kinase inhibition? 
To address this question, different EML4-ALK variants as well as other ALK fusion 
genes were expressed in Ba/F3 and NIH3T3 cells and analyzed for protein stability and 
sensitivity to ALK and heat shock protein 90 (HSP90) inhibitors.  
2. Which mutations in EML4-ALK can induce resistance to ALK kinase inhibitors? 
To find novel resistance mutations in EML4-ALK, different methods for accelerated 
random mutagenesis were applied on EML4-ALK expressing Ba/F3 cells. In addition, 
two structurally diverse ALK kinase inhibitors were used to define specific sensitivity 
patterns for each resistance mutation and each inhibitor.  
3. Which additional mechanisms of resistance can develop in EML4-ALK 
expressing cells after long-term treatment with ALK kinase inhibitors? 
To analyze resistance mechanisms after long-term ALK inhibitor treatment, an EML4-
ALK expressing human cell line was exposed to increasing concentrations of ALK 
inhibitor for 6 month. Resistant clones were then genetically analyzed to define possible 
resistance mechanisms.  
In summary, this work aims to decipher genetic variations in EML4-ALK expressing cells 
that influence the sensitivity to ALK kinase inhibitors. Hopefully, these findings will lead 
to a better understanding of resistance in EML4-ALK positive tumors and help to 
enhance tumor control in the future.  
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3 Materials and Methods 
 
3.1 Chemicals, Enzymes and solutions 
Chemicals were purchased from CarlRoth and Sigma-Aldrich, enzymes were purchased 
from Fermentas and Invitrogen. Cell culture reagents were purchased from PAA.  
 
3.2 General DNA/RNA procedures 
Standard procedures such as polymerase chain reaction (PCR), gel electrophoresis, 
restriction enzyme digestion, DNA ligations and bacterial transformations were carried 
out according to the manufacturers protocol. Mini-preparations of plasmid DNA were 
performed using the NucleoSpin mini-kit (Machery Nagel), midi-preparations were 
performed using the NucleoBond Xtra Midi EF kit (Machery Nagel). If not stated 
otherwise, sequencing was performed at the Cologne Center for Genomics (CCG) using 
standard dideoxy-sequencing. 
RNA was isolated using TRIZOL-reagent (Invitrogen) following the manufactures 
protocol. Therefore, 1 µg of RNA was transcribed into cDNA using the Superscript II 
reverse transcriptase (Invitrogen, #18064). 100 ng of cDNA were used to amplify the 
gene of interest (SOS1-ADCY3). After enzymatic digestion, the cDNA was ligated into 
the pBabe-puro backbone and transformed into chemically competent DH5α bacteria. 
 
3.3 cDNA and plasmids 
pMA-3FLAG-EML4-ALK v1/v2/v3b and KIF5b-ALK cDNAs were synthesized at GeneArt. 
All EML4-ALK cDNAs and the KIF5b-ALK cDNA were cloned into the retroviral pBabe-
puro backbone. pDONR-EML4-ALK v3a and NPM1-ALK were synthesized at 
GeneScript and cloned into the retroviral pBabe-puro gateway (GW) backbone. Site 
directed mutagenesis was performed following the manufactures protocol (Stratagene) 
to generate pBabe-puro EML4-ALK v3a from pBabe-puro EML4-ALK v3b, pBabe-puro 
EML4-ALK del223 from pBabe-puro EML4-ALK v3a, pBabe-puro EML4-ALK del346 
and 702 from pBabe-puro EML4-ALK v2. In addition, site directed mutagenesis was 
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performed to integrate the following point mutations:  
pBabe-puro EML4-ALK v1 F1174L  
pBabe-puro EML4-ALK v1 L1196M 
pBabe-puro EML4-ALK v1 D1203N 
pBabe-puro GW EML4-ALK v3a F1174L  
pBabe-puro GW EML4-ALK v3a L1196M 
pBabe-puro GW EML4-ALK v3a G1269S 
pBabe-puro GW EML4-ALK v3a L1198P 
 
3.4 Oligonucleotides 
Oligonucleotides were purchased from Eurofins MWG Operon. 
 
 
 
 
 
 
 
Primers used to sequence from the pBabe-puro backbone into the cloned cDNA (from 5’ to 3’)
pBb5’  CTTTATCCAGCCCTCAC 
pBb3’  ACCCTAACTGACACACATTCC
Primers used to sequence pBabe-puro GW EML4-ALK cDNA (from 5’ to 3’)
EA_F_393  TCTCATTCTAATGATCAAAGTCCACA
EA_R_951  CCTGTTCAGAGCACACTTCAGG
EA_R_1440  GATTTCCCATAGCAGCACTCC
EA_F_1355  CTGTGCCATGCTGCCAGT
EA_F_2007  CCAACGTACGGCTCCTG
EA_R_2097  GACAGTACAGCTTCCCTCCAG
ALK_R_493  GCTGAGATTGAACTGGAGCA
ALK_F_417   CAGTTGGTGCTGGAGCTG
ALK_F_986  CAAGCACACCATCCTGAGTC
ALK_R_1078  GCAGCTGGGCAATGTACC
ALK_F_1488  CACACTCCTCAATGGCAGGT
ALK_R_1554  GGACATCAGTGGTACTGAGCAATAG
ALK_R_2124  CACCTCCACGCTCAGGTT
ALK_F_2578  GACTGGAGAATAACTCCTCGGTTC
ALK_R_2636  ATCATTCCAGCCACCTCCA
ALK_F_2955  AACTGCAGTCACTGTGAGGTAGAC
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Primers used to sequence pBabe-puro EML4-ALK cDNA (from 5’ to 3’)
EA_WP25F  GCCGAATTCTGATGGCTTC
EA_WP 417F  AAAGAGGAAAGCCACAGCAA
EA_WP 952F  CACACCGACTGCGTGAAG
EA_WP 1389F TACGAGAAGCCCAAGTTCGT
EA_WP 1950F  GACTTCCACCCTAGCGGAAC
EA_WP 2416F  TCAGCGATCTGAAAGAGGTG
EA_WP 2922F  CCCGGGACATCTACAGAGC
EA_WP 3437F  TACAACAAGCTCTGGCAAGG
EA_WP 283R  TGGTGATGCAGCTCATGG
EA_WP 787R  GTCCGGATGTCGTCGTAGTT
EA_WP 1266R  ACCACCTCGTTGGTGGTCT
EA_WP 1800R  CCTGCACCTCAATCTGGAAG
EA_WP 2303R  CTGCAGTTCTTGGTGCTTCC
EA_WP 2784R  GTGCAGCAGGTCCAGCAT
EA_WP 3288R  GGCGGTGTTGATCACGTC
EA_WP 3784R  CTAGAGGGTTCCAGCAGCAG
Primers used for EML4-ALK site-directed mutagenesis (from 5’ to 3’)
F1174L_F_WP_SDM  AAGCCCTGATCATCAGCAAGTTAAACCACCAGAAC
F1174L_R_WP_SDM  GTTCTGGTGGTTTAACTTGCTGATGATCAGGGCTT
L1196M_F_WP_SDM  CCCCGGTTCATCCTGATGGAACTGATGGCTG
L1196M_R_WP_SDM  CAGCCATCAGTTCCATCAGGATGAACCGGGG
L1198P_F_WP_SDM  CATCCTGCTGGAACCGATGGCTGGAGGCG
L1198P_R_WP_SDM  CGCCTCCAGCCATCGGTTCCAGCAGGATG
G1269S_F_WP_SDM  GAGTGGCCAAGATCAGCGACTTCGGCATG
G1269S_R_WP_SDM  CATGCCGAAGTCGCTGATCTTGGCCACTC
D1203N_F_WP_SDM  CTGATGGCTGGAGGCAACCTGAAGTCCTTCC
D1203N_R_WP_SDM  GGAAGGACTTCAGGTTGCCTCCAGCCATCAG
EA_V5A_WP_F_SDM  AAAGCGTGTCCAGCATACCGGCGGAAGCAC
EA_V5A_WP_R_SDM  GTGCTTCCGCCGGTATGCTGGACACGCTTT
V2_DEL299-346_F_SDM  GCTGTTCAACTACGAGGATAGCGTGACCCTGA
V2_DEL299-346_R_SDM  TCAGGGTCACGCTATCCTCGTAGTTGAACAGC
V2_DEL299-702_F_SDM  GCTGTTCAACTACGAGGTGGTGTCCGAGAACG
V2_DEL299-702_R_SDM  CGTTCTCGGACACCACCTCGTAGTTGAACAGC
EA_3B_DEL224-234F  ATCATCAACCAGGCCTACCGGCGGAAGCAC
EA_3B_DEL224-234R  GTGCTTCCGCCGGTAGGCCTGGTTGATGAT
Primers used to amplify EML4-ALK for deep sequencing (from 5’ to 3’)
EA_F1_454amp_adapt  CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTGATCCCAGTGTGGTGGTACAT
EA_R1_454amp_adapt  CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACACTTGCTTTCTGGAGTTTGTCTGT
EA_F2_454amp_adapt  CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTCCTCTTCACAACCTCTCCAAA
EA_R2_454amp_adapt  CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACATCCTGTTCAGAGCACACTTCAG
EA_F3_454amp_adapt  CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTCTGCAAGTGGCTGTGAAGAC
EA_R3_454amp_adapt   CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACAGAGAAAAGATTTCCCATAGCAG
EA_F4_454amp_adapt  CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTCAGACACATGGTCCTTTGGAG
EA_R4_454amp_adapt  CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACACGAAGGAGGGTTGGACTG
EA_F5_454amp_adapt  CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTGGACACGTGAATATGGCATTC
EA_R5_454amp_adapt  CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACACCTAACTGACACACATTCCACAG
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3.5 Cell lines 
NIH3T3, HEK293T and H3122 cells were purchased from ATCC, Ba/F3wt and Ba/F3BCR-
ABL cells were a kind gift from Nikolas von Bubnoff.   
NIH3T3 cells were cultured in DMEM high glucose (Gibco) supplemented with 10% calf 
serum (CS) and 100 U/ml penicillin/streptomycin (P/S). Ba/F3 cells were cultured in 
RPMI (Gibco) supplemented with 20% fetal calf serum (FCS) and 100 U/ml 
penicillin/streptomycin. HEK293T cells were cultured in DMEM high glucose (Gibco) 
supplemented with 10% fetal calf serum (FCS) and 100 U/ml penicillin/streptomycin, 
H3122 cells were cultured in RPMI (Gibco) supplemented with 10% fetal calf serum 
(FCS) and 100 U/ml penicillin/streptomycin. All adherend cells were routinely passaged 
at approximately 80% of confluence. Therefore, culture medium was removed, cells 
were washed with 5 ml of cold PBS and incubated in 2 ml Trypsin/EDTA until cells were 
detached. Trypsin was inactivated by the addition of 10 ml of culture medium and cells 
Primers used to sequence EML4-ALK deep sequencing amplicons by dideoxy sequencing (from 5’ to 3’)
454amp_seq_F  CCCTCGCGCCATCA
454amp_seq_R  GCTGGCAAGGCGCATA
Primers used to amplify SOS1-ADCY3 (from 5’ to 3’)
SOS_5_amp  CAGGGATCCATGCAGGCGCAGCAG
ADCY3_3_amp  CAGGAATTCTCAGGAGTTGTCCACCACCT
Primers used to sequence verify the cloned SOS1-ADCY3 cDNA (from 5’ to 3’)
ADCY3_F_37  TGCCCTACGAGTTTTTCAGC
SOS-ADCY3_F_276  GCAATAGCTGATGCCCAATC
SOS-ADCY3_F_704  GCCCTTTGTCTCCAATTCAA
SOS-ADCY3_F_1280  ATACCACCAGCTGCGGATTA
SOS-ADCY3_F_1758  GCACCAGCTTCCTCAAAGTC
SOS-ADCY3_F_2275  AGAAGCTTGTGGCCTTCTCA
SOS-ADCY3_F_2770  ACTACTTCTCCCGCCACGTA
SOS-ADCY3_F_3275  CATGAAGGATACGCTCACCA
SOS-ADCY3_R_125  GATGAACTTGCCCCTGGAC
SOS-ADCY3_R_603  TGGAAGGCTCTTCGTCAGTT
SOS-ADCY3_R_1130  GAACTGCTGCTGGTCCTTCT
SOS-ADCY3_R_1613  AAACTCCCCTTTCAGGCAGT
SOS-ADCY3_R_2096  CTCCTTCTCCACCGAGTAGC
SOS-ADCY3_R_2594  CCAGGCATAGAGGTTGATGG
SOS-ADCY3_R_3108  TGGGATTGTCCAGGAGAGAG
SOS-ADCY3_R_3596 GGGGAAGGTGGCTAGCTTAT
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were plated or diluted accordingly.  
Suspension cells were passaged by appropriate dilution of the cell/medium suspension. 
All cells were incubated at 37 °C and 5% CO2.  
For long-term storage, cells were harvested, centrifuged for 5 minutes at 200 g and 4 °C 
before resuspending the cells in growth medium with 10% DMSO. After slowly cooling 
down to -80 °C, cells were moved to liquid nitrogen (-196 °C) the next day. 
 
3.6 Compounds 
Compounds were purchased from Selleck Chemicals, AxonMedchem or extracted from 
tablets and diluted in DMSO. PF02341066 describes a racemix mixture, whereas 
crizotinib represents only the active R-enantiomer of PF02341066. Bortezomib was a 
kind gift from Nina Reinart. 
 
3.7 Virus production 
8*10 5  HEK293T cells were plated on a 6 cm dish in DMEM + 10% FCS without P/S and 
incubated over night at 37 °C. The next day, cells were transfected with retroviral 
plasmids. Therefore, 12 µl of TransIT were added dropwise to 400 µl of Opti-Mem. In a 
separate tube, 4 µg of pBabe-puro expression plasmid were mixed with 4 µg of pCL-eco 
packaging plasmid in 400 µl of Opti-Mem. After 5 minutes of incubation, both tubes 
were mixed carefully and incubated at room temperature for 20 minutes. After 
incubation, Trans-IT/plasmid mixture was added dropwise to HEK293T cells. The next 
day, medium was removed and changed to DMEM + 30% FCS with P/S. After 24 hours, 
medium was collected and cells were cultured again for 24 hours with fresh medium. 
The next day, both collected supernatants were mixed, centrifuged at 300 g for 5 
minutes, filtered through a 0.45 µm filter to remove cellular debris and frozen in aliquots 
at -80 °C. 
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3.8 Stable cDNA expression 
Ba/F3 cells were thawed and cultured in RPMI + 20% FCS + 10 ng/ml IL-3 (R&D 
Systems; 403-ML-050). After 48 hours, 4*106 proliferating cells were transferred into a 
25 cm2 flask, with 5 ml total medium, 10 ng/ml IL-3, 8 µg/ml polybrene and 1 ml 
retroviral supernatant. Cells were incubated for 24-48 hours before adding 2 ml of fresh 
medium (20% FCS, no IL-3) with 4 µl puromycin (3 mg/ml). 96 hours post-transduction, 
cells were centrifuged at 200 g for 5 minutes and resuspended in 6 ml fresh medium 
(20% FCS) with 3 µl puromycin (3 mg/ml).  After 2-3 weeks, oncogene-expressing cells 
started to proliferate and were expanded and frozen in liquid nitrogen for long-term 
storage. 
 
3.9 Soft agar assay  
3.9.1 Preparation of bottom agar 
Agarose Type IX ultra low (Sigma Aldrich) was prepared as a 2% stock using ddH2O. 
Agar was heated to 95 °C for at least 30 minutes using a thermoblock, allowed to cool 
down to approximately 60 °C before adding equal volumes of 2x DMEM medium with 
20% FCS and 2% P/S to the agar to get a final 1% agar/DMEM solution. 50 µL of this 
mixture were then added into each 96-well and allowed to solidify at 4 °C for 10 
minutes. 
3.9.2 Preparation of top agar 
For top agar preparation, a stock solution of 1.2% was prepared in the same manner as 
described for the bottom agar, but cooled down slowly to 40 °C before use. NIH3T3 
cells were detached by trypsine before cell numbers were determined using the Z2-
coulter counter from Beckman Coulter. For each 96-well, 2000 cells were mixed with the 
0.6% agar/DMEM solution and plated in 50 µl of cell/agar suspension on top of the 
previously prepared, pre-warmed bottom agar 96-well plate. To ensure top agar 
solidification, the plates were placed at 4 °C for 10 minutes and incubated at 37 °C in a 
humidified incubator for 14-28 days. During incubation time, the medium was carefully 
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changed when appropriate. After colony formation, pictures of each well were taken 
using the Scanalyzer imaging system (Lemnatec). 
 
3.10 Whole cell lysates, protein extraction and quantification 
Cells were washed with cold PBS and lysed in lysis buffer (20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X‑100 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM 
PMSF, complete Protease Inhibitors Cocktail and Phosphatase Inhibitors Cocktail Set 
II). After 15 minutes of incubation on ice, lysates were centrifuged at 22,000 g for 20 
minutes at 4 °C. Supernatant was collected and protein concentrations were measured 
using the BCA Protein Assay (ThermoScientific). Cell lysates were stored at -20 °C.  
 
3.11 Discontinuous SDS polyacrylamide gel electrophoresis 
Proteins were separated on Novex® 4-12% Tris-Glycin polyacrylamide gel (Invitrogen) 
by electrophoresis. 5x Laemmli buffer (5x SDS sample buffer: 250 mM Tris (pH 6.8), 
50% glycerol, 5% β‑mercaptoethanol, 10% SDS and 0.05% bromophenol blue) was 
added to 50 µg of protein before denaturing each sample at 95°C for 10 minutes. 
Electrophoresis was performed in SDS running buffer (192 mM Glycin, 25 mM Tris-HCl, 
0.1% SDS) at 100V in XCell SureLock Gel Chambers (Invitrogen). PageRuler™ Plus 
Prestained Protein Ladder (Fermentas) was used as a standard. 
 
3.12 Immunoblotting 
Electrophoresis separated proteins were transferred from the polyacrylamide gel to a 
nitrocellulose membrane using the XCell-II Blot Module (Invitrogen) and 1x transfer 
buffer (25 mM Tris-HCl, 192 mM Glycin, 20% methanol). The transfer was performed for 
three hours at 25 V. After transfer, membranes were blocked in 5% skimmed milk in 
TBS-T (50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.05% Tween-20) before over night 
incubation at 4 °C with primary antibodies in 5% milk in TBS-T. The following antibodies 
were used: p-AKT Ser473, total AKT, p-ERK, total ERK, pALK Tyr1604 and pALK 
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Tyr1278/1282/1283 (Bossi et al., 2010) from Cell Signaling, Actin from MP Biomedical 
and total ALK from Bethyl Laboratories. Secondary HRP conjugated antibodies were 
purchased from New England Biolabs (NEB) and diluted 1:3000 in 5% milk TBS-T 
before incubation with the membrane for 30 minutes at room temperature. After 
incubation, the membrane was washed three times with TBS-T at room temperature. X-
ray films and ECL solution were purchased from GE Healthcare and used according to 
the manufacturer´s instructions. Immunoblot signal intensities were measured using 
ImageJ (1.42q). 
The human phosphor-receptor tyrosine kinase array (R&D Systems) was performed 
according the manufacturer´s instructions 
  
3.13 Immunohistochemistry 
NIH3T3 cells stably expressing the respective EML4-ALK cDNAs were seeded with 60% 
confluence on 22 mm diameter glass slides. The next day, slides were removed from 
the culture dish, membranes were stabilized in PBS + 3 mM MgCl2 and fixed in 4% PFA 
for 15 minutes before incubation in PBS + 0.2% TritonX for 5 minutes to rehydrate the 
slides. Primary anti-ALK antibody was diluted 1:1000 in TBS-T + 1% BSA. Slides were 
incubated with the primary antibody in a humified chamber for 1 hour at room 
temperature. FITC-labeled secondary antibody was diluted 1:800 in TBS-T + 1% BSA 
plus 1:1000 DAPI. After three washing steps in TBS-T, glass slides were incubated with 
secondary antibody for 45 minutes in a dark humified chamber. After again three 
washing steps, slides were washed in Ethanol and dried in the dark for 45 minutes 
before covering slides on coverslips with SlowFade Gold (Invitrogen). Pictures were 
taken on an Aristoplan machine (Leica/Leitz Microsystems) using a 400-fold 
magnification. 
 
3.14 Viability assays 
Ba/F3 cells were counted using the Z2-coulter counter from Beckman Coulter. 20,000 
cells were plated into each well of a sterile 96-well microtiter plate using a multichannel 
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pipette. The next day, compounds were added in serial dilutions. Cellular viability was 
determined after 96 hours of treatment by measuring cellular ATP content using the 
CellTiter-Glo Assay (Promega). Luminescence was measured on a Mithras LB 940 
Plate Reader (Berthold Technologies). GI50 values were determined using the following 
R package (Frommolt and Thomas, 2008). 
 
3.15 Generation of ALK inhibitor resistant H3122 cells 
H3122 cells were seeded at ~70% confluence in 6-well dishes in RPMI with 10% FBS. 
PF02341066 was added at a starting concentration of 30 nM, and cells were treated 
with fresh drug-containing medium every ~72 hours. Drug concentrations were 
increased as soon as the cells reached ~90% of confluence. The concentration of 
PF02341066 was increased until a final concentration of 3 µM was achieved. The 
resulting polyclonal resistant cells (designated as H3122 PR) were maintained in RPMI 
with 10% FCS containing 3 µM PF02341066 or 1.5 µM crizotinib. 
 
3.16 Trypan-blue staining 
Ba/F3 cells expressing the indicated EML4-ALK cDNA were treated with ALK kinase 
inhibitors for 48 hours. Cells were resuspended and diluted 1:1 with trypan-blue before 
being transferred to a Neubauer-Chamber were trypan blue negative (viable) and 
positive (dead) cells were counted under the light microscope. 
 
3.17 Mutagenesis screens 
To generate randomly mutated pBabe-puro GW EML4-ALK v3a plasmids, a saturation 
mutagenesis screen was performed as has been described previously (Azam et al., 
2003; Emery et al., 2009). Therefore, mismatch-repair-deficient E.coli (strain XL1-Red, 
Stratagene) were transformed with the EML4-ALK cDNA and propagated for 48 or 72 
hours. Plasmids were isolated and expanded in XL1-Blue bacteria. Isolated plasmids 
were packaged in retroviruses followed by infection of Ba/F3 cells as described above. 
24 hours after infection, cells were cultured in the absence of IL-3 and presence of ALK 
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kinase inhibitor (750 nM/ 1000 nM/ 1500 nM of PF02341066) to only allow proliferation 
of resistant clones with an active kinase. Surviving cells were expanded before the 
isolation of genomic DNA. Mutant inserts were recovered by PCR using the primers 
stated above. The amplified EML4-ALK fragments were pooled and sequenced on a GS 
Flex instrument at the Cologne Center for Genomics (CCG). The raw data was aligned 
and visualized by IGV.  
In a second mutagenesis screen, EML4-ALK-expressing Ba/F3 cells were treated with 
N-ethyl-N-nitrosourea (ENU; 100 µg/ml) over night to induce random mutations in the 
cells genomes. After 24 hours of incubation, cells were centrifuged, washed in PBS and 
cultured in the presence of the ALK inhibitor (750 nM/ 1000 nM/ 1500 nM of 
PF02341066) to select for resistant and viable clones. Again, genomic inserts were 
PCR-amplified and sequenced as described above.  
To differentiate the clonal origin of the two resistance mutations found, dideoxy 
sequencing was performed for each polyclonal resistant clone separately.  
 
3.18 Structural modeling 
Resistance mutations were modeled into ALK (PDB-codes: 2XP2 (crizotinib) and 2XB7 
(TAE684) by Daniel Rauh, using PyMol software (Schroedinger).  
 
3.19 Mass spectrometry 
After rigorous vortexing, 30 µl of Protein A/G agarose breads were mixed with 5 µg of 
anti-ALK antibody (Bethyl laboratories) and 500 µl of cold PBS. After 4 hours of 
incubation on a rotating shaker at 4 °C, beads were washed three times with cold PBS 
before adding 500 µg of whole cell lysate and subsequent incubation on a rotating 
shaker over night at 4 °C. The next day, beads were washed three times, mixed with 30 
µl Laemmli buffer and run on a polyacrylamide gel as indicated above. After protein 
separation, the polyacrylamide gel was stained with coomassie solution for protein 
visualization. Each lane was cut out and analyzed by mass spectrometry at the CMMC 
bioanalytic service in Cologne.  
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3.20 RNA-sequencing 
After RNA extraction and cDNA library construction, cDNAs were sheared and 
fragments were size-selected to a fragment length range of 300 - 400 base pairs using 
a bioanalyzer. cDNA fragments were then loaded into separate flow-cell lanes on an 
Illumina Genome Analyzer II. 41,570,899 fragments of 95-mer reads were obtained, 
leading to ~7.6 gigabases of total sequence. First, duplicate pair reads and low-quality 
reads were discarded, leading to 37,836,347 distinct reads. The achieved mean 
sequence coverage of the annotated transcriptome was approximately 30x. Data 
analysis was performed using Velvet+Oases for de novo assembly (Zerbino and Birney, 
2008; Zerbino and Schulz, unplublished data). Reconstructed transcripts were then 
compared to given transcript annotations to recover gene fusion events. In addition, 
potential fusion transcripts were identified by recurrent conflicts in the assignment of 
pair-end reads to only one gene.  
 
3.21 In silico domain search 
Protein domains were searched using SimpleModularArchitectureResearchTool 
(http://smart.embl-heidelberg.de/) 
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4 Results 
 
4.1 Differential protein stability and ALK inhibitor sensitivity of 
EML4-ALK fusion variants  
 
4.1.1 EML4-ALK variants transform NIH3T3 cells 
EML4-ALK translocations lead to a fusion protein whose kinase is, due to its persistent 
homodimerization, constantly activated. Depending on the breakpoint between EML4 
and ALK, different variants develop that differ in size of the fusion transcript. 
In order to analyze the transformation capacity of different EML4-ALK variants, the most 
frequent variants were cloned into the retroviral pBabe-puro backbone and used for 
retroviral transduction of NIH3T3 cells. These murine fibroblasts spontaneously 
immortalized after serial subcultivation, exhibit a hypertriploid karyotype but do not show 
a transformed phenotype (Jainchill et al., 1969; Todaro and Green, 1963). After plating 
NIH3T3 cells into a layer of soft-agar, non-transformed NIH3T3 cells stop dividing. If, 
however, an oncogene is expressed in these cells, the lack of a polar surface does not 
inhibit cell division anymore. Thus, the transformed NIH3T3 cells become insensitive to 
anti growth signals, leading to colony formation in soft agar (Hanahan and Weinberg, 
2000). After plating NIH3T3 cells expressing EML4-ALK v1, v2 and v3a in soft agar, all 
variants formed similar numbers of colonies, indicating comparable transformation 
capacities in NIH3T3 cells (Figure 7) (Chen et al., 2008; Greulich et al., 2005).  
 
Figure 7 NIH3T3 cells transduced with pBabe empty vector (e.v.) or the 
indicated EML4-ALK variant were plated in soft agar. Pictures were taken after 
14 days of incubation using a Scanalyzer imaging system (Lemnatec). 
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4.1.2 EML4-ALK variants induce differential sensitivity to ALK kinase 
inhibition 
In order to test, whether different EML4-ALK fusion variants show differential sensitivity 
to ALK kinase inhibitors, the Ba/F3 cell line model was used. These murine pre-B-cells 
are dependent on constant interleukin-3 (IL-3) stimulation for cell survival. To prevent 
rapid induction of apoptosis, Ba/F3wt cell culture medium is usually supplemented with 
10 ng/ml of exogenous IL-3. Oncogenes (e.g. oncogenic RTKs) can substitute for the 
essential IL-3 signaling, and thereby render the cells IL-3 independent. Thus, the 
expressed oncogenes prevent the induction of apoptosis and make these cells 
independent of external growth signals (Hanahan and Weinberg, 2000). This cell line 
model has been used extensively to monitor transformation capacity and kinase 
inhibitor sensitivity of several EGFR mutations (Jiang et al., 2005; Yuza et al., 2007). 
Again, virus particles were generated for all 
ALK fusion genes and used to transduce 
Ba/F3wt cells. Stable expression of EML4-
ALK v1, v2, v3a and v3b rendered Ba/F3 
cells independent of IL-3, thus, as 
expected, all variants showed transforming 
capacity. In addition, all cells expressing 
different EML4-ALK variants showed 
similar proliferation rates (Figure 8).  
To analyze the sensitivity of each variant to 
ALK kinase inhibition, fusion gene 
expressing cells were plated into 96-well 
plates and treated with increasing 
concentration of the aminopyridine ALK 
inhibitor crizotinib (PF02341066). After incubation for 96 hours, the ATP content in each 
well was measured using an ATP-dependent luminescence reaction (cell titer glow, 
Promega). EML4-ALK variants v1 and v3b showed no significant differences in 
sensitivity, represented by the half-maximal growth inhibitory concentration (“GI50 
values”) (GI50s 470 nM, Figure 9). Interestingly, Ba/F3 cells expressing the longest and 
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Figure 8 Ba/F3 cells expressing the indicated 
EML4-ALK variants were plated at equal cell 
numbers at day 0. Cell counts were determined 
at each of the following 4 days, error bars 
indicate SEM. 
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the shortest of the four EML4-ALK variants (i.e. v2 and v3a) showed considerable 
differences in crizotinib sensitivity (GI50 150 nM and 1000 nM respectively). To test, 
whether this phenotype was restricted to this specific ALK inhibitor, the same set of cells 
was treated with the structurally different diaminopyrimidine ALK inhibitor TAE684 
(Figure 9). Here, the same pattern of sensitivity was observed, with v2 being the most  
 
sensitive (GI50 0.3 nM) and v3a the most resistant (GI50 24 nM) variant of EML4-ALK.  
These findings show, that different EML4-ALK variants elicit differential sensitivity to 
ALK kinase inhibition, independent of the binding mode of the inhibitor to the kinase. 
Even though both inhibitors bind to the hinge region of the kinase, the three dimensional 
expansion into the ATP-binding pocket differs for both compounds (Figure 10).  
 
 
 
 
 
 
Figure 9 Ba/F3 cells expressing the indicated EML4-ALK variants were treated with increasing 
concentrations of crizotinib (left) or TAE684 (right). Viability was determined after 96 hours of 
treatment by measuring the ATP content in each well. Viability is expressed as a function of 
compound dose and ATP-content, relative to the DMSO-treated control. Each data point represents 
the mean of three independent experiments with triplicate measurements, error bars indicate SEM. 
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One possible explanation for the differences in sensitivity could be a differential 
accessibility of the inhibitors to the ATP-binding pocket of the kinase. Even though both 
variants harbor the same proportion of ALK, the three dimensional arrangement of the 
fusion protein might vary depending on the proportion of EML4 that is fused to ALK, 
thereby hindering inhibitor binding. To test this 
hypothesis, EML4-ALK v2 and v3a expressing 
Ba/F3 cells were treated with increasing 
concentrations of crizotinib and lysed after 1 
hour of treatment. Proteins were separated on 
a polyacrylamide gel before immunoblotting 
was performed to monitor ALK 
phosphorylation. As has already been shown 
for another ALK kinase inhibitor, no 
differences in ALK phosphorylation were 
observed for concentration from 300 to 3000 
nM of crizotinib (Figure 11) (Lovly et al., 
2011). 
Figure 11 EML4-ALK v2 and v3a 
expressing Ba/F3 cells were treated with the 
indicated concentrations of crizotinib for 1h. 
Whole cell lysates were stained for pALK, 
ALK and actin by immunoblotting. 
Figure 10 Crystal structures showing crizotinib (left) and TAE684 (right) bound to the kinase 
domain of ALK. Both compounds are shown as black sticks, the hinge-region, helix-C and 
DFG-motif are labeled. PyMol file was generated by Christian Grütter, TU Dortmund, Germany.  
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To verify these results in an independent cell line model, ALK phosphorylation was 
monitored in NIH3T3 cells expressing EML4-ALK variants 2 and 3a respectively. 
NIH3T3 cells expressing the respective variants were seeded on 6-well dishes and 
treated the next day with increasing concentrations of crizotinib for 1 hour. Again, 
immunostainings did not show any differences in ALK phosphorylation at crizotinib 
concentrations from 300 to 3000 nM (Figure 12 A). Treatment with lower doses of 
crizotinib supported this finding, showing a dose dependent inhibition of ALK 
phosphorylation between 30 and 300 nM of crizotinib. Consistent with previous findings, 
crizotinib treatment led to a dose dependent decrease in ERK phosphorylation, whereas 
no changes in AKT phosphorylation were observed (Figure 12 B) (Takezawa et al., 
2011). In addition, the same pattern of phosphorylation was shown for EML4-ALK v1 
(Figure 12 C). Thus, the binding capacity of crizotinib to the ATP-binding pocket does 
not seem to be altered in the three EML4-ALK variants studied.  
 
 
 
 
Figure 12 A/B/C NIH3T3 cells expressing the indicated EML4-ALK cDNAs were treated with the 
indicated concentrations of crizotinib for 1 hour. Whole cell lysates were stained for pALK, ALK, pAKT, 
pERK and ERK or actin as loading control. Black arrows indicate the respective EML4-ALK variant 
(top, bottom) or unspecific staining (central). 
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4.1.3 EML4-ALK variants show differences in intracellular distribution 
All EML4-ALK variants studied harbor exon 20 to exon 29 of ALK, which are fused to 
different breakpoints within the EML4 gene (Figure 2, Figure 13). Thus, the proportion 
of EML4 that is fused to ALK is probably responsible for the observed differences in 
inhibitor sensitivity (Figure 9, Figure 13).  
Even though the exact function of EML proteins is unknown, it is believed that these 
proteins represent a class of microtubule destabilizers (Pollmann et al., 2006). At the N-
terminal of the EML4 protein, a coiled-coiled domain is located which is essential for the 
oncogenic capacity of EML4-ALK (Soda et al., 2007). At the C-terminal end of the 
coiled-coiled domain, a HELP domain is followed by nine WD40 domains. It is thought, 
that the HELP domain of EML4 mediates tubulin binding (Pollmann et al., 2006), while 
WD40 domains are involved in a wide range of cellular functions (Xu and Min, 2011). In 
order to analyze the intracellular localization of different EML4-ALK variants, NIH3T3 
cells expressing EML4-ALK v1, v2, v3a were stained for ALK by immunohistochemistry. 
EML4-ALK variants 1 and 2, both containing a HELP domain, were mainly abundant in 
the cytoplasm (Figure 14). Variant 3a, which lacks the HELP domain, was equally 
distributed throughout the cytoplasm and the nucleus, suggesting, that the HELP 
domain retains the fusion protein in the cytoplasm (Figure 13, Figure 14) (Pollmann et 
al., 2006). However, since variant 1 and variant 2 showed the same intracellular 
Figure 13 Schematic presentation of EML4-ALK variants 1, 2, 3a and 3b. The breakpoint between 
EML4 and ALK is indicated with a black arrow. The additional 33-bp sequence derived from intron 6 of 
EML4 that differentiates v3b from v3a is shown as a light gray box. 
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localization, but showed differences in sensitivity, the intracellular distribution does not 
seem to highly influence the sensitivity to ALK kinase inhibitors. 
 
 
 
4.1.4 EML4-ALK v2 and v3a interact with HSP90 proteins 
As shown in Figure 13, an additional structural difference between EML4-ALK variant 2 
and variant 3a is the number of WD40 domains. These domains are one of the most 
prevalent domains in eukaryotic proteins and are thought to arise from genetic 
duplications. They form β-propeller like structures that allow the formation of a wide 
range of protein-protein and protein-DNA interactions. However, these interactions, and 
therefore also potential binding partners, are difficult to predict (Xu and Min, 2011). To 
analyze if the WD40 domains in EML4-ALK v2 promote interactions with specific 
binding partners, immunoprecipitations of EML4-ALK v2 and v3a were performed 
(Figure 15).  
Figure 14 NIH3T3 cells expressing the indicated EML4-ALK variants 
were fixed on glass slides and stained for total ALK (FITC) and nuclei 
(DAPI). Pictures were taken at 400-fold magnification. 
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Pulled proteins were analyzed by mass-spectrometry for interacting proteins. As has 
been described previously, high amounts of HSP90 proteins were found to be 
associated to both variants. This interaction potentially explains the described 
dependency of EML4-ALK expressing cells to HSP90 chaperonage (Katayama et al., 
2011; Normant et al., 2011). However, negative controls consisting of beads and lysates 
only also yielded some HSP90 peptides, arguing for an unspecific binding of HSP90 
proteins to the agarose-beads. The only protein that was found in immunoprecipitations 
and not in controls was AMPD2 (an AMP deaminase). However, no robust differences 
between v2 and v3a were observed (Table 1, page 51).  
 
 
 
 
Figure 15 NIH3T3 cells transduced with pBabe empty vector, EML4-ALK v2 or EML4-ALK v3a were 
lysed to perform immunoprecipitations of ALK. First, total ALK protein levels were stained on a 
nitrocellulose membrane to control proper precipitation of ALK (left). Second, immunoprecipitated 
proteins were separated on a polyacrylamide gel, stained with coomassie (right) and subsequently 
analyzed by mass-spectometry. Arrows indicate the respective EML4-ALK fusion variant. 
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4.1.5 ALK inhibitors induce a dose dependent EML4-ALK protein 
degradation 
Since no differences in ALK phosphorylation were observed after 1 hour of treatment, 
longer crizotinib treatments were performed to analyze potential feedback mechanisms 
that re-activate kinase activity. Therefore, immunoblotting was performed using lysates 
of EML4-ALK expressing NIH3T3 cells that were treated for 24 hours with ALK inhibitor. 
Interestingly, treatment with 1 µM or 3 µM of crizotinib led to a reduction of total ALK 
protein in variant 2 expressing cells. In contrast, in variant 3a expressing cells total ALK 
levels were only reduced at 3 µM crizotinib, but not at 1 µM drug concentrations (Figure 
16 A). To confirm this effect in another cell line, the same assay was repeated using 
Ba/F3 cells. Here, again, the dose-dependent effect of ALK degradation was much 
more pronounced for variant 2 compared to variant 3a (Figure 16 B). Treatment of 
Table 1 Immunoprecipitated proteins are listed for both EML4-ALK variants. EML4-ALK proteins are 
highlighted in light gray, proteins that were only found in ALK immunoprecipitations are highlighted in 
dark gray. Proteins that were also found in antibody negative controls are shown with a white 
background. 
Lysates'NIH3T3'EML40ALKv2'+'beads'+'antibody Lysates'NIH3T3'EML40ALKv3a'+'beads'+'antibody
!!ALBU_HUMAN!Serum!albumin !!ALBU_HUMAN!Serum!albumin
!!ALBU_MOUSE!Serum!albumin !!ALBU_MOUSE!Serum!albumin
!!ALK_HUMAN!ALK!tyrosine!kinase!receptor !!ALK_HUMAN!ALK!tyrosine!kinase!receptor
!!ALK_MOUSE!ALK!tyrosine!kinase!receptor !!AMPD2_HUMAN!AMP!deaminase2
!!AMPD2_HUMAN!AMP!deaminase2 !!AMPD2_MOUSE!AMP!deaminase2
!!AMPD2_MOUSE!AMP!deaminase2 !!CH60_HUMAN!60kDa!heat!shock!protein,!mitochondrial
!!EMAL4_HUMAN!Echinoderm!microtubuleHassociated!proteinHlike!4 !!CH60_MOUSE!60kDa!heat!shock!protein,!mitochondrial
!!EMAL4_MOUSE!Echinoderm!microtubuleHassociated!proteinHlike!4 !!EF2_HUMAN!Elongation!factor!2
!!HS90B_HUMAN!Heat!shock!protein!HSP90Hbeta !!EF2_MOUSE!Elongation!factor!2
!!HS90B_MOUSE!Heat!shock!protein!HSP90Hbeta !!ENPL_HUMAN!Endoplasmin
!!HSP7C_HUMAN!Heat!shock!cognate!71kDa!protein !!ENPL_MOUSE!Endoplasmin
!!HSP7C_MOUSE!Heat!shock!cognate!71kDa!protein !!GRP78_HUMAN!78kDa!glucoseHregulated!protein
!!K1C10_HUMAN!Keratin,!type!I!cytoskeletal!10 !!GRP78_MOUSE!78kDa!glucoseHregulated!protein
!!K1C10_MOUSE!Keratin,!type!I!cytoskeletal!10 !!HS90A_HUMAN!Heat!shock!protein!HSP90Halpha
!!K22E_HUMAN!Keratin,!type!II!cytoskeletal!2!epidermal !!HS90A_MOUSE!Heat!shock!protein!HSP90Halpha
!!K2C1_HUMAN!Keratin,!type!II!cytoskeletal!1! !!HS90B_HUMAN!Heat!shock!protein!HSP90Hbeta
!!K2C1_MOUSE!Keratin,!type!II!cytoskeletal!1 !!HS90B_MOUSE!Heat!shock!protein!HSP90Hbeta
!!K2C5_MOUSE!Keratin,!type!II!cytoskeletal!5 !!HSP7C_HUMAN!Heat!shock!cognate!71kDa!protein
!!K2C8_MOUSE!Keratin,!type!II!cytoskeletal!8 !!HSP7C_MOUSE!Heat!shock!cognate!71kDa!protein
!!K1C10_HUMAN!Keratin,!type!I!cytoskeletal!10
!!K1C10_MOUSE!Keratin,!type!I!cytoskeletal!10
!!K22E_HUMAN!Keratin,!type!II!cytoskeletal!2!epidermal
!!K2C1_HUMAN!Keratin,!type!II!cytoskeletal!1
!!K2C1_MOUSE!Keratin,!type!II!cytoskeletal!1
!!KPYM_HUMAN!Pyruvate!kinase!isozymes!M1/M2
!!KPYM_MOUSE!Pyruvate!kinase!isozymes!M1/M2
!!MYH9_HUMAN!MyosinH9
!!MYH9_MOUSE!MyosinH9
 52 
these cells with 1 µM of TAE684 for 24 hours also induced degradation of variant 2, but 
not of variant 3a (Figure 16 C). Thus, ALK kinase inhibition induces a fusion variant 
dependent degree of EML4-ALK protein degradation after long-term treatment.  
 
4.1.6 Crizotinib induced EML4-ALK degradation is proteasome 
independent 
Most proteins are degraded in the cytosolic proteasome machinery. To test, whether the 
observed degradation of EML4-ALK is mediated by the proteasome, Ba/F3 cells 
expressing different EML4-ALK variants were first treated with increasing 
concentrations of the proteasome inhibitor bortezomib. Viability measurements in cells 
expressing EML4-ALK variants 2 and 3a revealed no differences in sensitivity. 
However, in both cases, addition of exogenous IL-3 into the medium was not capable to 
rescue this phenotype, indicating an EML4-ALK unrelated toxicity of bortezomib in these 
cells (Figure 17 A). To circumvent this problem, EML4-ALK expressing NIH3T3 cells 
were treated with 3 µM crizotinib, 100 nM bortezomib or both compounds combined for 
24 hours. In this setting, a proteasome dependent degradation of EML4-ALK should 
lead to increased ALK levels in the bortezomib treated cells and should rescue the 
crizotinib induced degradation in crizotinib + bortezomib treated cells. Interestingly, the 
inhibition of proteasomal activity did not increase the protein levels of EML4-ALK 
Figure 16 NIH3T3 cells (A/C) or Ba/F3 cells (B) expressing the indicated EML4-ALK cDNAs were 
treated with increasing concentrations of crizotinib (A/B) or TAE684 (C). After 24h of treatment, 
lysates were prepared and analyzed for pALK, ALK and actin protein levels by immunoblotting. 
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compared to DMSO treated cell, nor did it rescue the crizotinib-induced EML4-ALK 
degradation in the combination treatment. This finding implies a proteasome 
independent degradation of EML4-ALK in these cells (Figure 17 B).  
 
 
 
 
 
 
 
 
4.1.7 EML4-ALK variants show differences in protein stability 
In order to analyze the basal protein stabilities of the different fusions, EML4-ALK 
expressing Ba/F3 and NIH3T3 cells were treated with 50 µg/ml or 100 µg/ml of 
cycloheximide for 24 hours respectively. Cycloheximide is an inhibitor of the protein 
biosynthesis, thereby uncovering differences in the half-life of proteins. Immunoblotting 
after DMSO and cycloheximide treatment showed remarkable differences in total ALK 
levels. The most pronounced difference of total ALK protein was observed between 
untreated and treated cells expressing EML4-ALK variant 2. EML4-ALK variant 1 
showed an intermediate difference in protein levels, whereas EML4-ALK variant 3a 
showed almost no reduction in total ALK protein levels after treatment (Figure 18 A/B).  
Figure 17 A Ba/F3 cells expressing the indicated EML4-ALK variants were treated with increasing 
concentrations of bortezomib. Viability was determined after 72 hours of treatment and is expressed 
as a function of compound dose and ATP-content, relative to DMSO-treated controls. B NIH3T3 
cells expressing the indicated EML4-ALK cDNAs were treated with 3 µM crizotinib, 100 nM 
bortezomib or both compounds combined. After 24 hours of treatment, whole cell lysates were 
prepared and analyzed for pALK, ALK and actin protein levels by immunoblotting. 
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Thus, the proportion of EML4 that is fused to ALK, strongly influences the stability of the 
fusion protein. This effect might also play a role in the drug 
binding induced degradation of the protein as well as the 
differences in ALK kinase inhibitor sensitivity (Figure 9, 
Figure 16). Interestingly, even though EML4-ALK v3b was 
more sensitive to ALK inhibitor treatment compared to v3a, 
protein levels after treatment with cycloheximide did not 
vary significantly, indicating that ALK kinase inhibitor 
sensitivity is not a direct consequence of the different 
protein stabilities in these cells (Figure 19). 
 
4.1.8 Artificial EML4-ALK deletion mutants modify ALK inhibitor 
sensitivity 
To evaluate the effect of EML4 on the degradation kinetics of EML4-ALK fusion proteins 
and on the kinase inhibitor sensitivity of EML4-ALK expressing cells, site directed 
Figure 19 Total ALK signal 
intensity ratios after 
cycloheximide treatment of 
Ba/F3 are shown for EML4-
ALK v3a and v3b. Error bars 
indicate SEM. 
Figure 18 EML4-ALK expressing Ba/F3 (A) or NIH3T3 (B) cells were treated with DMSO 
or cycloheximide for 24 hours. Whole cell lysates were stained for total ALK (top). Signal 
intensity of each staining was analyzed using ImageJ software. Signal ratios of 
DMSO/CHX are shown for each EML4-ALK variant as an average of three independent 
experiments, error bars indicate SEM (bottom). 
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mutagenesis was performed on different EML4-ALK variants to generate artificial 
deletion constructs. With variant 2 being the longest and least stable variant (Figure 13, 
Figure 18), deletions at the 5’ end of EML4-ALK might increase basal protein stability 
and decrease ALK inhibitor sensitivity. Variant 2 was used as a template to remove 
amino acids 299-346 to generate variant del346 (lacking the first WD40 domain next to 
the HELP domain) or 299-702 to generate variant del702 (lacking the first seven WD40 
domains). Variant 3a was used to remove amino acids 61-223, generating variant 
del223 which is similar to EML4-ALK variant 5 (Figure 20 A). Importantly, all deletion 
constructs maintained the coiled-coiled domain of EML4, essential for continuous ALK 
kinase activation (Soda et al., 2007). As expected, all of the deletion constructs 
transformed Ba/F3 cells, however, depending on the respective deletion, a distinct 
sensitivity pattern was observed after treatment with ALK kinase inhibitors. Ba/F3 cells 
expressing EML4-ALK del346 were as sensitive as variant 2 expressing cells (Figure 
20 B). By contrast, Ba/F3 cells expressing del702 were much more resistant to kinase 
inhibition compared to cells expressing variant 2, being almost as resistant as cells 
expressing variant 3a (Figure 20 B). EML4-ALK del223 expressing cells showed no 
significant differences in crizotinib sensitivity, indicating that the region of amino acids 
61-223 does not influence the sensitivity of the EML4-ALK variants to kinase inhibition. 
Even though EML4-ALK v3a and del223 were the most resistant ALK fusion genes 
tested, both variants were still more sensitive to ALK inhibition compared to BCR-ABL 
expressing Ba/F3 (Figure 20 C).  
4.1.9 EML4-ALK deletion mutants show differences in protein stability 
Treatment of Ba/F3 cells expressing EML4-ALK del346 and del702 with cycloheximide, 
revealed striking differences in protein stability. Here, EML4-ALK del346 seemed 
slightly less stable compared to EML4-ALK v2, whereas the deletion in EML4-ALK 
del702 increased protein stability dramatically (Figure 20 B). Cells expressing EML4-
ALK del223 displayed no degradation of the fusion protein after 24 hours of 
cycloheximide treatment, supporting the notion that amino acids 61-223 in EML4 do not 
seem to have a high impact on the protein properties (Figure 20 C).  
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Figure 20 A Schematic presentation of EML4-ALK v1, v2 and v3a as well as the deletion 
constructs EML4-ALK del346, del702 and del223. B/C Ba/F3 cells expressing the indicated 
EML4-ALK deletion variants were treated with increasing concentrations of crizotinib before 
viability was determined after 72 hours. Each data point represents the mean of three 
independent experiments with triplicate measurements, error bars indicate SEM (left). Whole 
cell lysates from Ba/F3 cells expressing the indicated EML4-ALK deletion variants were 
prepared after 24 hours treatment with DMSO or 50 µg/ml cycloheximide and stained for total 
ALK levels by immunoblotting (right). 
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Overall, these findings indicate that variations in EML4 can, depending on the affected 
amino acids, highly influence the overall stability of the EML4-ALK fusion protein. 
Furthermore, these findings might, to some extend, also translate into the differences in 
sensitivity to ALK kinase inhibition. 
 
4.1.10 EML4-ALK variants induce differential sensitivity to HSP90 
inhibition 
As stated above, previous publications have shown that EML4-ALK expressing cells are 
sensitive to HSP90 inhibition. Treatment with HSP90 inhibitors leads to a decrease of 
total ALK protein levels and thereby induces cytotoxicity in EML4-ALK expressing cells. 
Importantly, this effect is independent of ALK inhibitor resistance mutation status (Chen 
et al., 2010; Katayama et al., 2011; Normant et al., 2011). To explore if different EML4-
ALK variants induce differential sensitivity to HSP90 inhibition, Ba/F3 cells expressing 
EML4-ALK variants 2 and 3a were treated with increasing concentrations of 17-DMAG, 
an ansamycin antibiotic derivative. Ba/F3 cells expressing variant 2 were 2-fold more 
sensitive to HSP90 inhibition compared to Ba/F3 cells expressing variant 3a (GI50s of 
115 nM and 226 nM respectively). It must be mentioned, that Ba/F3 cells expressing 
EML4-ALK v3a were almost as sensitive as the IL-3-supplemented control, indicating 
that other HSP90 clients, and not only the EML4-ALK v3a degradation itself, induced 
the detected reduction in viability (Figure 21 A). To confirm these results, the synthetic 
HSP90 inhibitor AUY922 was used to treat EML4-ALK v2 and v3a expressing cells. 
Here, the same pattern of sensitivity was observed. However, the high intrinsic 
sensitivity of IL-3-treated cells to this HSP90 inhibitor made these experiments difficult 
to interpret (compare EML4-ALK v2 + IL-3 with EML4-ALK v3a and EML4-ALK v3a + IL-
3, Figure 21 B). Interestingly, cells expressing EML4-ALK variant 1 were slightly more 
sensitive to HSP90 treatment compared to cells expressing variant 2 (Figure 22 A). 
These findings show, that ALK kinase inhibitor sensitivity and the intrinsic stability of the 
fusion protein alone do not predict the sensitivity to HSP90 inhibitors (compare Figures 
9, 18, 21 and Figure 22). However, the intrinsic protein stability seems to impact the 
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dependency on HSP90 chaperonage, since no difference in HSP90 inhibitor sensitivity 
was observed for Ba/F3 cells expressing EML4-ALK v3a and v3b (Figure 22 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Ba/F3 cells expressing the indicated EML4-ALK variants were treated with 
increasing concentrations of 17-DMAG (A) or AUY922 (B). Viability was determined after 
72 hours and is expressed as a function of compound dose and ATP-content, relative to 
the DMSO-treated controls. Each data point shows the mean of three independent 
experiments with triplicate measurements, error bars indicate SEM.   
Figure 22 A/B Ba/F3 cells expressing the indicated EML4-ALK variants were treated with 
increasing concentrations of 17-DMAG. Viability was determined after 72 hours and is 
expressed as a function of compound dose and ATP-content, relative to the DMSO-treated 
controls. Each data point shows the mean of three (A) or two (B) independent experiments 
with triplicate measurements, error bars indicate SEM. 
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4.1.11 Inhibitor sensitivity and protein stability of other ALK 
fusions  
To analyze the effect of the N-terminal fusion partner on kinase inhibitor sensitivity and 
protein stability in other ALK fusion genes, Ba/F3 cells expressing KIF5b-ALK and 
NPM1-ALK were generated (Figure 23 A). Both fusion genes rendered Ba/F3 cells IL-3 
independent, as has been described previously (Galkin et al., 2007; Morris et al., 1994; 
Takeuchi et al., 2009). After treatment with crizotinib, Ba/F3 cells expressing KIF5b-ALK 
were as sensitive as cells expressing EML4-ALK v2. Ba/F3 cells expressing NPM1-ALK 
showed a sensitivity pattern similar to EML4-ALK v1 and v3b (Figure 23 B). After 
treatment with cycloheximide, KIF5b-ALK and NPM1-ALK showed a similar degree of 
degradation, even though the sensitivity to crizotinib varied substantially (Figure 23 C). 
EML4-ALK v2 and v3a were again the two fusion proteins with the lowest and highest 
protein stability respectively. Hence, a correlation between ALK kinase inhibitor 
sensitivity and overall protein stability only seems to apply for EML4-ALK fusion 
proteins, with the exception of EML4-ALK v3b.  
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4.1.12 Synergistic effects after combined ALK and HSP90 
inhibitor treatment  
Treatment of EML4-ALK v1 and EML4-ALK v2 expressing Ba/F3 cells with HSP90 or 
ALK inhibitors revealed different sensitivity patterns for these two inhibitors respectively. 
Thus, sensitivity to ALK and HSP90 inhibition seems to be mediated by different 
Figure 23 A Schematic presentation of EML4-ALK variants, KIF5b-ALK and NPM1-ALK. B Ba/F3 
cells expressing the indicated ALK fusion genes were treated with increasing concentrations of 
crizotinib. Viability was determined after 72 hours and is expressed as a function of compound dose 
and ATP-content, relative of the DMSO-treated control. Each data point shows the mean of two 
independent experiments with triplicate measurements, error bars indicate SEM. C Ba/F3 cells 
expressing the indicated ALK fusion genes were treated with DMSO or 50 µg/ml cycloheximide for 24 
hours. Whole cell lysates were prepared and stained for total ALK by immunoblotting. 
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mechanisms and might therefore lead to an additive effect in a combined treatment. To 
test this hypothesis, EML4-ALK v1, v2 and v3a as well as KIF5b-ALK and BCR-ABL 
expressing Ba/F3 cells were treated with increasing concentrations of one of the two 
inhibitors alone or both compounds combined, each at the same concentration. 
Strikingly, in all ALK fusion-gene expressing cells, treatment with increasing 
concentrations of crizotinib or 17-DMAG alone was less cytotoxic compared to the 
combined treatment (Figure 24 A). Further analysis using an algorithm generated by 
Martin Peifer et al. revealed a synergistic effect in all ALK fusion-gene expressing cells, 
but not in BCR-ABL expressing Ba/F3 cells (Figure 24 B) (Peifer et al., 2010). The 
combined compound concentration leading to the highest synergistic effect varied 
depending on the respective fusion gene. In EML4-ALK v2 and KIF5b-ALK expressing 
cells, the highest synergy was observed at 80 nM of crizotinib and 17-DMAG, whereas 
the highest synergy in EML4-ALK v3a expressing cells was observed at 160 nM of each 
inhibitor. GI50 values for the combined treatment, calculated under the assumption that 
both compounds are equally concentrated, were 1.2- to 2.3-fold lower in these cells 
compared to the single drug GI50 of the more potent compound (Table 2, ratio 1, page 
61). For unknown reasons, combination treatment in EML4-ALK v1 expressing cells 
induced the lowest synergy in all ALK fusion-gene expressing cells (Figure 24 A/B). 
Interestingly, the higher the ratio between the higher and the lower GI50 value of single 
HSP90 and ALK inhibitor treatments, the lower the synergy after combination treatment 
(Table 2, ratio 2, page 61). As expected, BCR-ABL expressing cells did not show any 
synergistic cytotoxic effects after the combined treatment of HSP90 and ALK inhibitors. 
Here, only the effect of HSP90 inhibition reduced cellular viability, which could not be 
enhanced by ALK kinase inhibition (Figure 24 A).  
 
Table 2 GI50 values (nM) of crizotinib, 17-DAMG or an equal combination of both 
compounds in Ba/F3 cells expressing different fusion genes. 
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Figure 24 A Ba/F3 cells expressing the indicated fusion genes were treated with increasing 
concentrations of crizotinib, 17-DMAG or both compounds combined (at equal concentrations). 
Viability was determined after 96 hours and is expressed as a function of compound dose and 
ATP-content relative to the DMSO-treated control. Each data point shows the mean of two 
independent experiments with triplicate measurements, error bars indicate SEM. B Viability data 
was analyzed for synergy and visualized as a heatmap. 
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Thus, different ALK fusion genes show differences in protein stability and induce 
differential sensitivity to ALK and HSP90 inhibitors, which might explain some of the 
heterogeneous responses to crizotinib treatment in the clinic. Furthermore, combining 
ALK and HSP90 inhibitors results in synergistic cytotoxicity in ALK fusion gene 
expressing cells  
 
 
4.2 Different EML4-ALK mutations confer various levels of 
resistance to structurally diverse ALK kinase inhibitors 
 
4.2.1 Known crizotinib resistance mutations are highly sensitive to 
TAE684 
In 2010, a L1196M “gatekeeper mutation” has been reported in an EML4-ALK positive 
patient that has been treated with crizotinib for 5 month before relapse (Choi et al., 
2010). Furthermore, the same mutation has been described one year later in an 
experimentally raised crizotinib resistant EML4-ALK positive cell line (Katayama et al., 
2011). In the case of L1196M, as it is known for many other “gatekeeper mutations”, the 
bulky methionine side chain is thought to interfere with inhibitor binding (Choi et al., 
2010). However, structural modeling of this mutation suggested that a structurally 
unrelated ALK kinase inhibitor, like the diamino-pyrimidine scaffold of TAE684, should 
still be able to bind the mutated kinase (Galkin et al., 2007). In addition to this 
“gatekeeper mutation”, another mutation, F1174L, has been described in a patient with 
an inflammatory myofibroblastic tumour (IMT) (Butrynski et al., 2010; Sasaki et al., 
2010a). This patient has been treated with crizotinib, but showed disease progression. 
Sequencing of the tumor revealed the F1174L mutation in the kinase domain of the 
translocated ALK, which has been previously described as a kinase-activating mutation 
in neuroblastoma (Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; 
Mosse et al., 2008; Sasaki et al., 2010a). Thus, the activating nature of the F1174L 
mutation decreases the sensitivity to the type-II kinase inhibitor crizotinib, which only 
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binds to the inactive kinase conformation of ALK. The type-I 
kinase inhibitor TAE684 however, binds to the active kinase 
conformation of ALK and thus, should be able to overcome 
resistance mediated by this mutation (Galkin et al., 2007). 
To test these hypotheses, both mutations were expressed 
in the EML4-ALK v1 positive NSCLC cell line H3122 
(Figure 25). At that time, the purified R-enantiomer 
crizotinib was not commercially available, which is why the 
racemic mixture (PF02341066) was used. As expected, 
both mutations induced resistance to PF02341066 (Figure 
26). More precisely, EML4-ALKF1174L only induced 
resistance at lower concentrations of PF02341066, but was 
sensitive to higher compound concentrations. The L1196M 
mutation also induced 
resistance to high 
concentrations of 
PF02341066. After 
treating these cells with 
TAE684, both mutants 
were highly sensitive to 
kinase inhibition, with the 
F1174L expressing cells 
being exceptionally 
sensitive (Figure 26). 
  
 
 
 
Figure 25 Whole cell lysates 
from H3122 cells expressing 
the indicated EML4-ALK 
cDNAs were stained for 
protein levels of pALK, ALK 
and Actin (Heuckmann et 
al., 2011). 
Figure 26 EML4-ALK cDNA expressing H3122 cells were treated with 
PF02341066 or TAE684. After 96 hours of treatment, viable and dead 
cells were counted using trypan-blue (Heuckmann et al., 2011). 
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4.2.2 Novel crizotinib resistance mutation increases ALK kinase 
activity 
To validate these finding in an independent cell line model, both mutated fusion genes 
were expressed in Ba/F3 cells and treated with increasing concentrations of both 
compounds. In addition to the two resistance mutations described above, another 
mutation, G1269S (located adjacent to the DFG-motif of the kinase), was expressed in 
these cells. Structural modeling of this mutation, performed by Daniel Rauh and 
colleagues, suggested a steric clash with PF02341066, but not with TAE684 (Figure 
27). Immunoblotting of these mutated fusion proteins showed an increased basal ALK  
phosphorylation in EML4-ALKF1174L and EML4-ALKG1269S expressing cells, but not in 
EML4-ALKL1196M expressing cells (Figure 28 A) (Choi et al., 2010; Sasaki et al., 2010a). 
As expected, the expression of F1174L led to a slight increase in resistance, whereas 
the mutations L1196M and G1269S induced a high level of resistance to PF02341066 
(Figure 28 B). Again, all resistance mutations were sensitive to treatment with TAE684, 
with the activating mutations (EML4-ALKF1174L and EML4-ALKG1269S) being extremely 
sensitive compared to EML4-ALKwt and EML4-ALKL1196M (Figure 28 C). In line with 
these findings, the phosphorylation of ALK in these mutants was completely abolished 
after treatment with 30 nM TAE684, but remained unchanged after treatment with up to 
2.5 µM of PF02341066 (Figure 29). 
Figure 27 Crystal structures of ALK bound to PF02341066 (left) and TAE684 (right). Serine 
residue 1269 is shown as sphere to highlight steric hindrance induced by the G1269S mutation. 
PyMol file was generated by Chritian Grütter, TU Dortmund, Germany.  
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Thus, kinase-activating mutations (F1174L and G1269S) can induce resistance to the 
type-II inhibitor PF02341066, which can be overcome by TAE684 due to its ability to 
bind the active kinase conformation. Structural modeling of TAE684 bound to G1269S 
mutated ALK however suggests that an 
amino acid larger than serine might, due to 
steric hindrance, be able to induce 
resistance to TAE684 (Figure 27). Steric 
hindrance is also the proposed resistance 
mechanism for the L1196M mutation and 
PF02341066. Here, TAE684 is able to 
overcome the induced resistance by a 
different binding mode that prevents the 
approximation to the M1196 residue (Choi et 
al., 2010; Katayama et al., 2011).  
 
Figure 29 Ba/F3 cells expressing the 
indicated EML4-ALK mutations were treated 
with PF02341066 (left) or TAE684 (right). 
ALK phosphorylation was monitored by 
immunoblotting after 6 hours of treatment 
(Heuckmann et al., 2011). 
Figure 28 A Whole cell lysates of Ba/F3 cells expressing the indicated EML4-ALK cDNAs were 
stained for pALK, ALK and Actin protein levels. B/C Ba/F3 cells expressing the indicated mutations of 
EML4-ALK were treated with PF02341066 (B) or TAE684 (C). After 48 hours of treatment, viable and 
dead cells were counted using trypan-blue, error bars indicate SEM of three independent experiments 
(Heuckmann et al., 2011). 
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4.2.3 Novel EML4-ALK resistance mutations induce resistance to 
crizotinib and TAE684  
In order to discover additional ALK resistance mutations, two functional saturation 
mutagenesis screens were performed (Azam et al., 2003; Emery et al., 2009). First, 
EML4-ALK v3a cDNAs were randomly mutagenized by propagation in repair-deficient 
E.coli. The harvested cDNAs were used to generate virus particles for Ba/F3 cell 
transduction (Yuza et al., 2007). After transduction, cells were cultured without 
exogenous IL-3, but with different concentrations of PF02341066 (750 nM, 1000 nM, 
1500 nM) to select for cells with (i) an active ALK kinase and (ii) an ALK kinase that is 
resistant to PF02341066 kinase inhibition (Figure 30). Resistant cells were expanded 
and genomic DNA was isolated for massively parallel picoliter reactor pyrosequencing-
by-synthesis sequencing of the EML4-ALK fusion gene (Thomas et al., 2006). The most 
predominant mutations were L1198P (49%) and D1203N (12%), two novel resistance 
mutations (Figure 31 A). 
  
Figure 30 Schematic presentation of the “saturated mutagenesis” screen	  (Heuckmann et al., 2011). 
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Interestingly, both mutations induced resistance not only to PF02341066 (v3a wt GI50: 
1.5 µM; L1198P GI50: 3.4 µM; D1203N GI50: 3.4 µM), but also to TAE684 (v3a wt GI50: 
56 nM; L1198P GI50: 624 nM; D1203N GI50: 604 nM) (Figure 31 B). To verify these 
findings, the respective mutations were introduced into the EML4-ALKwt plasmid by site 
Figure 31 A Crystal structures showing PF02341066 (left) and TAE684 (right) bound to ALK. Amino 
acids that confer resistance to ALK inhibitors if mutated are indicated (G1123S, F1174L, L1196M, 
L1198P, D1203N, G1269S) (picture by Christian Grütter, TU Dortmund, Germany) B Polyclonal Ba/F3 
cultures expressing the indicated resistance mutations were treated with increasing concentrations of 
PF02341066 (left) or TAE684 (right). Viability was determined after 96 hours of treatment and is 
expressed as a function of compound dose and ATP-content relative to DMSO-treated controls 
(Heuckmann et al., 2011). 
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directed mutagenesis to ensure the expression of only one mutation per clone. EML4-
ALKL1198P expressing Ba/F3 cells showed a general increase in kinase activity, thereby 
explaining the resistance to PF02341066 (Figure 32 A). Counting of viable cells after 
ALK kinase inhibitor treatment using trypan-blue confirmed the previous results (Figure 
32 B). Furthermore, resistance by L1198P was characterized by stable ALK 
phosphorylation at concentrations up to 2.5 µM of PF02341066 and 300 nM of TAE684 
(Figure 32 C). The same applied for the resistance mutation D1203N, even though this 
effect was less pronounced. Furthermore, the D1203N mutation did not increase the 
basal kinase activation, showing that increased kinase activation is not the resistance 
mechanisms to PF02341066 for this mutation (Figure 33 A/B).  
 
Figure 32 A EML4-ALKwt and EML4-ALKL1198P expressing Ba/F3 cells were lysed and stained for 
phosphorylation of ALK. B EML4-ALKwt and EML4-ALKL1198P expressing Ba/F3 cells were treated with 
1 µM of PF02341066 or 500 nM of TAE684 respectively. Viable cells were counted using trypan blue 
after 48 hours of treatment. C Ba/F3 cells stably expressing EML4-ALKwt or EML4-ALKL1198P were 
treated with increasing concentrations of ALK inhibitor. Whole cell lysates were stained for ALK 
phosphorylation. Actin was used as loading control (Heuckmann et al., 2011). 
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To verify these findings in 
an orthogonal 
mutagenesis screen, 
EML4-ALK expressing 
Ba/F3 cells were treated 
with the chemical mutagen 
N – etyl – N - nitrosourea 
(ENU) (Bradeen et al., 
2006). After ENU 
treatment, cells were 
cultured in different 
concentrations of 
PF02341066 (750 nM, 
1000 nM, 1500 nM) until resistant clones emerged (Figure 34). Here again, most of the 
resistant cells expressed the L1198P mutations and showed a high degree of resistance 
to treatment with PF02341066 and TAE684 (Figure 35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 A EML4-ALKwt and EML4-ALKD1203N expressing Ba/F3 
cells were lysed and stained for phosphorylation of ALK. B Ba/F3 
cells stably expressing EML4-ALKwt or EML4-ALKD1203N were 
treated with increasing concentrations of ALK inhibitor. Whole cell 
lysates were stained for ALK phosphorylation. Actin was used as 
loading control (Heuckmann et al., 2011). 
 
Figure 34 Schematic presentation of the N-ethyl-N-nitrosourea mutagenesis 
screen (Heuckmann et al., 2011). 
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In reference to the differential ALK kinase inhibitor sensitivity observed for different 
EML4-ALK variants, the L1198P mutation was introduced into EML4-ALK v2. As 
expected, treatment of EML4-ALK v2 and EML4-ALK v2L1198P expressing Ba/F3 cells 
with TAE684 revealed a dramatic increase in resistance of the mutated cells (Figure 
36). Thus, depending on the sensitivity of the wild type EML4-ALK variant, the L1198P 
mutation can induce a more than 100-fold 
increase in resistance (here; EML4-ALK 
v2wt: GI50 0.15 nM, EML4-ALK v2L1198P: GI50 
190 nM) 
 
4.2.4 Mechanisms of resistance in 
L1198P mutated ALK 
To explain the resistance phenotype 
induced by EML4-ALKL1198P, Daniel Rauh 
and colleagues performed structural 
modeling of L1198P in the crystal structure 
of ALK. Most in-cis resistance mutations 
that are known today shift the kinase 
Figure 36 Ba/F3 cells expressing the indicated 
EML4-ALK cDNAs were treated with increasing 
concentrations of TAE684. Viability is shown as 
a function of compound dose and ATP-content, 
relative to DMSO-treated controls. Error bars 
indicate SEM.  
Figure 35 ALK inhibitor resistant EML4-ALK expressing Ba/F3 cells that emerged after ENU 
treatment were incubated with increasing concentrations of PF02341066 (left) or TAE684 (right). 
Viability was measured after 96 hours of treatment and is expressed as a function of compound 
dose and ATP-content, relative to DMSO-treated controls. 
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equilibrium towards a higher kinase activity (e.g. F1174L mutations in ALK) or show 
direct contact with the inhibitor (e.g. T790M mutations in EGFR). The L1198P mutation 
is localized in the hinge region of the kinase, a region where ATP, PF02341066 and 
TAE684 bind. Leucine 1198 lies between two residues that form key hydrogen bonds to 
the backbone of PF02341066, and are therefore essential for inhibitor binding (Figure 
31 A). One of these residues, E1197, forms hydrogen bonds to K1267 and R1181 
(Figure 37). This interaction has recently been described as “molecular brake”, by 
shifting the equilibrium of the kinase into the more inactive state. This interaction 
network is proposed to be a common mechanism to regulate kinase activation (Chen et 
al., 2007). Even though leucine 1198 does not directly participate in this hydrogen 
network, it is known that proline residues can perturb the three dimensional 
arrangement of protein backbones (MacArthur and Thornton, 1991). Thus, the L1198P 
mutation might destroy the hydrogen network of the neighboring residues by changing 
Figure 37 Crystal structure of PF02341066 bound to the ALK kinase domain. 
The side chain of E1197 forms hydrogen bonds with K1267 at the N-terminal 
end of a loop segment that is connected to the activation loop. These 
interactions form the “molecular brake” that might be perturbed in L1198P 
mutated kinases. Picture by Christian Grütter, TU Dortmund, Germany 
(Heuckmann et al., 2011). 
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the protein backbone. This perturbation of the “molecular brake” could then lead to the 
increase of basal kinase activity that was observed in L1198P mutated cells, a 
mechanism to induce resistance to PF02341066 (Figure 31, Figure 32). In addition, 
crystal structures of ALK and TAE684 show, that the methoxy-group of TAE684 binds 
into a small cavity between the hinge region and the N-lobe of the kinase (Figure 38) 
(Bossi et al., 2010; Galkin et al., 2007). As mentioned above, the L1198P mutation 
should perturb the three dimensional arrangement of the protein backbone and might 
therefore disturb TAE684 binding (Figure 38).  
 
4.2.5 Mechanisms of resistance in D1203N mutated ALK 
The D1203N mutation lies at the lip of the ATP pocket and is in close proximity to both 
ALK inhibitors studied (Figure 31 A). However, the aspartatic acid and asparagine side 
chains point away from the inhibitors and towards the solvent, making a steric 
interaction as mechanism of resistance highly unlikely. In addition, the D1203N mutation 
does not increase the basal kinase activity. Thus, the mechanism of resistance for this 
mutation is currently unknown. However, a recent study from Katayama et al. found a 
G1202R mutation in an EML4-ALK positive, but crizotinib resistant tumor which induced 
resistance to crizotinib and TAE684 in a cellular model (Katayama et al., 2012). Hence, 
mutations at this specific region of ALK seem to mediate resistance to both ALK kinase 
inhibitors tested.  
Figure 38 Crystal structure of TAE684 (black sticks) bound to the ALK kinase domain (PDB-code: 
2XB7). The surface of the kinase and the compound are indicated as gray mesh. Amino acids forming 
a cavity that interacts with the methoxy-group of TAE684 are shown as spheres and labeled 
accordingly. L1198 (left) and P1198 (right) are shown as dark gray spheres.  
 74 
Thus, resistance induced by the mutations F1174L, L1196M and G1269S can be 
overcome by ALK inhibitors that bind to the active kinase conformation (type-I inhibitors) 
or that avoid interference with certain amino acid side chains (Sun et al., 2010). 
Furthermore, two novel resistance mutations (L1198P and D1203N) were shown to 
induce resistance to PF02341066 and TAE684, in the case of the L1198P mutation, 
most likely due to an increase in kinase activity and structural alterations of the kinase 
that hamper compound-kinase interactions. 
 
 
4.3 Overexpression of a novel fusion gene in ALK inhibitor 
resistant H3122 cells 
 
4.3.1 ALK kinase inhibitor resistant H3122 cells 
All resistance mechanisms described so far were defined by point mutations within the 
ALK kinase domain.  However, several tumors have been shown to develop gene 
amplifications (e.g. MET amplifications in EGFR mutated tumors) or other genetic 
events (e.g. aberrant splicing of BRAF in BRAF mutated cells) as resistance 
mechanisms (Engelman et al., 2007; Poulikakos et al., 2011; Turke et al., 2010). In 
order to analyze potential resistance mechanisms in EML4-ALK expressing cells in an 
unbiased fashion, H3122 cells were cultured with steadily increasing concentrations of 
PF02341066. H3122 cells express EML4-ALK variant 1 and have a GI50 of ≈ 1 µM if 
treated with PF02341066. After starting with 30 nM of PF02341066, drug concentrations 
were steadily increased as soon as cell became 90% confluent, up to concentrations of 
3 µM (designated as H3122 PR). At the same time, H3122 cells were treated with 
increasing concentrations of TAE684, up to concentrations of 1 µM (designated as 
H3122 TR). Viability measurements after treatment with increasing concentrations of 
PF02341066 showed a shift in GI50 values up to 6 µM, including the H3122 TR clone 
(Figure 39). Interestingly, all polyclonal H3122 PR clones also showed a high degree of 
resistance to TAE684 with a shift of GI50 values from 18 nM up to 10 µM (Figure 39). 
Thus, cross-resistance developed in all resistant H3122 clones, independently of the 
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inhibitor used to establish the cells. Sequencing of the complete ALK kinase domain in 
all of these clones did not reveal any mutations, indicating a resistance mechanism in-
trans.  
 
4.3.2 Co-occurring fusion genes in the EML4-ALK positive H3122 cell-
line  
To search for the novel “driver lesion” that induces resistance to ALK inhibition in these 
cells, RNA was isolated from the sensitive (H3122) and the resistant (H3122 PR1) cells 
to perform RNA-seq. As expected, the EML4-ALK variant 1 fusion transcript was 
detected in both clones with the same coverage (31-fold). In addition, a novel fusion 
gene, SOS1-ADCY3, was detected and further validated by RT-PCR. Surprisingly, the 
resistant and the sensitive H3122 clones expressed this fusion gene with identical 
coverage (32-fold), indicating that this fusion was not acquired in the ALK inhibitor 
resistant cells. Furthermore, the similar mRNA levels of EML4-ALK and SOS1-ADCY3 
show that transcriptional changes in the expression of these fusion genes are not 
responsible for the resistant phenotype (Figure 40).  
 
 
 
Figure 39 H3122 and ALK inhibitor resistant H3122 clones were treated with increasing 
concentrations of PF02341066 (left) or TAE684 (right). Viability is shown as a function of 
compound dose and ATP-content, relative to DMSO-treated controls. 
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The SOS1-ADCY3 transcript consists of the first seven exons of SOS1 and exon 2-21 
of ADCY3. To confirm the gene fusion on a genomic level, Roopika Menon designed a 
break-apart FISH assay. Therefore, a green- and a red-labeled bacterial artificial 
chromosome (BAC) are used for hybridization at the centromeric and telomeric end of 
each gene respectively. On a non-translocated chromosome, both dyes map close to 
each other, leading to a yellow (mixed green and red) light signal. If a translocation 
occurs, both probes map to more distant locations on the chromosome (or on different 
chromosomes), leading to a separate green and red signal (Figure 41 A). Sometimes, a 
loss of one of the signals may happen, as it has been the case for the SOS1 and 
ADCY3 probes in H3122 cells, thereby confirming translocations of these two genes 
(Figure 41 A/B). Furthermore, a fusion assay (combining a SOS1 and an ADCY3 
probe) confirmed the genomic fusion of these two genes (Figure 41 B). In order to 
determine if the generation of SOS1-ADCY3 was genetically linked to EML4-ALK, a 
double-fusion assay including FISH probes for ADCY3 and ALK was established. Here, 
the finding that each of the ADCY3 and ALK FISH assays generated a single green 
Figure 40 Schematic representation of the fusion transcript of SOS1-ADCY3 
and the location of each gene on chromosome 2. Below, breakpoint spanning 
reads from RNAseq are shown. (data generated by Lynnette Fernandez-
Cuesta, Max-Planck-Insitute for neurological research, Cologne, Germany). 
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signal was used (Figure 42 A/B). Thus, ALK and ADCY3 fusions on different 
chromosomes would lead to two green signals (one belonging to each gene). In H3122 
cells however, only one green signal was observed, suggesting a superposition of the 
two green signals as a consequence of both events happening in the same 
chromosome (Figure 42 B). 
Figure 41 A Schematic representation of the BAC-clone binding sites. B Metaphase chromosomes of 
H3122 cells were stained with green-fluorescent and red-fluorescent BAC probes for SOS1 and 
ADCY3 (data generated by Roopika Menon, Insitute of Pathology, University Bonn, Germany). 
Figure 42 A Schematic representation of the BAC-clone binding sites. B Metaphase chromosomes of 
H3122 cells were stained with green-fluorescent and red-fluorescent BAC probes for ADCY3 and ALK 
(data generated by Roopika Menon, Insitute of Pathology, University Bonn, Germany). 
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4.3.3 PKA and MAPK pathway activation in ALK inhibitor resistant 
H3122 cells 
SOS1 encodes for a guanine nucleotide exchange factor of RAS proteins. Hence, 
SOS1 facilitates the binding of GTP to RAS and thereby the activation of RAS proteins. 
However, the SOS1-ADCY3 fusion gene only consists of the first seven exons of SOS1, 
excluding the pleckstrin homology domain and the guanine nucleotide exchange factor 
domain from the fusion protein. Thus, a functional relevance of SOS1 activity in the 
fusion protein is highly unlikely (Figure 43). ADCY3 encodes for a transmembrane 
protein that catalyzes the formation of ATP to cyclic adenosine monophosphate (cAMP).  
	   
cAMP is a secondary messenger that regulates a diverse set of cellular responses 
including the activation of protein kinase A (PKA). To analyze if the SOS1-ADCY3 
fusion induces resistance by overexpression at the protein level and increased PKA 
activation, immunoblotting was performed using an antibody that binds to the N-terminal 
end of SOS1. Strikingly, all resistant clones tested showed an overexpression of the 
SOS1-ADCY3 fusion protein, whereas the parental cell line almost exclusively 
expressed SOS1wt. Interestingly, all resistant clones did not show any ALK 
phosphorylation, even though cells were cultured without drug for 24 hours (Figure 44 
Figure 43 Schematic representation of the SOS1-ADCY3 fusion protein, functional domains for the 
respective protein fragments are shown, the breakpoint is indicated with a black arrow. 
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A). In addition, resistant clones PR1 and PR5 showed a strong signal after staining for 
total ALK protein, which was at a higher molecular weight than the actual EML4-ALK v1 
protein (Figure 44 A). It remains unknown if these bands reflect unspecific staining or a 
translationally modified EML4-ALK protein. RNA-seq data confirmed no novel ALK 
fusion transcript on the mRNA level.  
Immunostainings for PI3K and MAPK pathway activation showed, that all resistant 
clones exhibited a dramatic increase in ERK phosphorylation, whereas the 
phosphorylation of AKT was not increased (Figure 44 B). Thus, overexpression of the 
SOS1-ADCY3 fusion protein might lead to an activation of the MAPK pathway. It has 
been described, that increased cAMP levels activate protein kinase A (PKA), inducing 
the phosphorylation of CREB and stimulation of the MAPK pathway via CRAF activation 
(Dumaz et al., 2006). Immunoblotting of pPKA in H3122 and PR1 cells showed an 
increased PKA phosphorylation in H3122 PR1 cells, supporting the hypothesis that this 
signaling circuit might be responsible for the elevated pERK levels in SOS1-ADCY3 
overexpressing cells (Figure 44 C). Staining for phosphorylation of 42 different receptor 
tyrosine kinases revealed a global reduction in RTK phosphorylation levels after the 
treatment of sensitive H3122 cells with PF02341066. Interestingly, almost no RTK 
phosphorylation was observed in the resistant cells, independent of inhibitor treatment 
(Figure 45). 
 
Figure 44 Whole cell lysates of H3122 and ALK inhibitor resistant H3122 clones were stained for 
pALK, ALK and SOS1 expression (A), AKT and ERK phosphorylation (B) and PKA activation (C).  
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4.3.4 SOS1-ADCY3 induces tumor formation in a NIH3T3 xenograft 
model 
To examine the oncogenicity of 
SOS1-ADCY3, the fusion gene was 
amplified from H3122 cDNA, cloned 
into the retroviral pBabe-puro 
backbone and expressed in NIH3T3 
cells. Interestingly, NIH3T3 cells 
expressing the SOS1-ADCY3 fusion 
Figure 46 NIH3T3 cells transduced with pBabe empty 
vector (e.v.), EML4-ALK v1 or SOS1-ADCY3 were 
plated in soft agar. Pictures were taken after 14 days 
of incubation. 
Figure 45 Indicated clones of H3122 cells were treated with DMSO or PF02341066 for 24 hours. After 
treatment, cells were lysed an incubated with phosphor-receptor tyrosine kinase antibodies spotted 
nitrocellulose membranes. In duplicate captured RTK levels were visualized using a HRP-conjugated 
pan phospho-tyrosine antibody. Signals on all four edges are positive controls. 
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gene did not form colonies in soft agar (Figure 46). However, after subcutaneous 
injection of fusion gene expressing NIH3T3 cells into nude mice, tumor formation was 
observed after 20 days of incubation (Figure 47). It remains to be seen, if extracellular 
growth factors, interactions with the extracellular matrix or differences in expression 
levels are responsible for the discrepancy between soft agar and xenograft 
experiments. Furthermore, ongoing studies will show if these cells also show elevated 
levels of phosphorylated ERK and might thereby be sensitive to MAPK pathway 
inhibition. 
  
 
 
Figure 47 NIH3T3 cells, transduced with pBabe-puro empty 
vector or SOS1-ADCY3 were subcutaneously injected into nude 
mice. Tumor formation was measured on regular bases. Data 
points represent the average of two tumors on two different 
mice, error bars indicate SEM (data generated by Jakob 
Schöttle, Max-Planck-Insitute for neurological research, 
Cologne, Germany). 
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5 Discussion  
In this study, striking differences in ALK inhibitor sensitivity were shown to be dependent 
on the expressed EML4-ALK variant, the specific resistance mutation and the kinase 
inhibitor used for treatment. 
First, a similar, EML4-ALK variant dependent, sensitivity pattern was observed for the 
two structurally unrelated ALK inhibitors crizotinib and TAE684, showing this effect to be 
independent of the respective binding mode of the inhibitor (Figure 9). Several 
mutations in other kinases (e.g. EGFR) have been shown to alter the affinity of ATP to 
the kinase or the interactions of the kinase with the drug, thereby leading to dramatic 
changes in drug binding capacities (Greulich et al., 2005; Sharma et al., 2007; Yuza et 
al., 2007). In the case of EML4-ALK, all variants harbor the wild-type kinase domain of 
ALK, excluding variations in ATP or compound affinity as possible explanation. 
Furthermore, previous studies have shown comparable levels of kinase activity in 
different EML4-ALK variants (Choi et al., 2008). In addition to the differential kinase 
inhibitor sensitivity, the overall fusion protein stability also varied dramatically depending 
on the ALK fusion partner, underlining the fusion partner and not the ALK kinase 
domain as the major factor influencing the fusion protein characteristics that were 
studied (Figure 18). Thus, in contrast to previous findings, the domain composition of 
the fusion partner and not the size of the fusion protein had a major impact on protein 
stability (De Sancho et al., 2009). Furthermore, in the case of EML4-ALK fusions, 
almost all variants showed a correlation between ALK kinase inhibitor sensitivity and 
overall protein stability, indicating that increased protein stability influences the 
sensitivity to ALK kinase inhibitors. A high turnover of protein might lead to a relatively 
low fraction of functional fusion proteins that are capable to bind the inhibitor. Thus, 
lower drug concentrations are needed to achieve a complete target inhibition. The only 
EML4-ALK variant that did not show such a correlation was EML4-ALK v3b. In this case, 
the, compared to v3a, 33 additional base pairs from the intronic region of EML4 are only 
present in EML4-ALK v3b, making a comparison with other EML4-ALK variants difficult.  
In addition to these general differences in protein turnover, ALK kinase inhibitor 
treatment induced a fusion variant and dose dependent degree of protein degradation 
(Figure 16). As a type-II inhibitor, crizotinib only binds to, and thereby stabilizes, the 
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inactive conformation of the kinase. This conformation of the kinase might be 
intrinsically less stable, leading to the drug-induced degradation of the protein. However, 
treatment with high doses of TAE684 also induced fusion protein degradation, indicating 
that other mechanisms may also play a leading role in the kinase inhibitor induced 
degradation. Inhibition of the proteasome did not rescue this drug induced kinase 
degradation, suggesting a proteasomal independent degradation mechanism (Figure 
17). One possibility could be a folding induced insolubility of the fusion protein after 
inhibitor binding, thereby forming insoluble aggregates which circumvent 
immunoblotting analysis and proteasomal degradation (Bonvini et al., 2004; Verhoef et 
al., 2002).  
In line with the findings of differential protein stability, cells expressing different ALK 
fusion genes showed differential sensitivity to HSP90 inhibition. Several groups have 
shown that EML4-ALK expressing cells are highly sensitive towards HSP90 inhibition 
(Chen et al., 2010; Katayama et al., 2011; Normant et al., 2011; Sasaki et al., 2010a). 
One reason for this dependency might be the fact that the protein folding properties of 
the fused proteins are disturbed by the somatically acquired fusion event. In the case of 
a gene fusion, the forming fusion protein has not developed evolutionarily and might 
therefore show defects in folding. These defects can be caused by hydrophobic 
residues at the breakpoint, which point towards the solvent and therefore require 
chaperonage of HSP90 or other chaperones. The broad spectrum of HSP90 inhibitor 
sensitivity observed in Ba/F3 cells expressing different EML4-ALK variants indicates 
that the amino acid composition of the breakpoint might dictate the degree of required 
chaperonage (Figures 21, 22 and 24).  
However, this dependency on HSP90 chaperonage does not correlate with sensitivity to 
ALK kinase inhibition, suggesting an independent mechanism of cytotoxicity. 
Surprisingly, after a combined treatment with HSP90 and ALK inhibitors, a synergistic 
effect was observed, clearly linking ALK and HSP90 inhibitor sensitivity in these cells 
(Figure 24) (Peifer et al., 2010). One possible functional link between HSP90 and ALK 
inhibitors might be the kinase inhibitor induced degradation of ALK (Figure 16). Even 
though, crizotinib induced EML4-ALK degradation was only observed at higher 
concentrations of this inhibitor, lower drug concentrations should also induce some 
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instability of the fusion protein. This destabilization might then be re-stabilized by 
HSP90 proteins, thereby preventing fusion protein degradation at low drug 
concentrations. In the combined treatment of ALK and HSP90 inhibitors, this 
stabilization by HSP90 proteins is blocked, inducing an accelerated degradation of the 
fusion proteins and subsequent cytotoxicity. The strongest synergy was observed in 
EML4-ALK v2 and KIF5b-ALK expressing cells, the most ALK inhibitor sensitive ALK 
fusions. However, both fusions were less sensitive to HSP90 inhibition compared to 
EML4-ALK v1, indicating that sensitivity to one of the drugs alone is not indicative for 
the synergy score after combination treatment. Interestingly, the smaller the ratio 
between the GI50 values of the less potent and the more potent compound, the higher 
the synergistic effect after combination treatment (Figure 24, Table 2 page 61 ratio 2). 
Thus, the interplay between these two compounds was maximized, if both compounds 
had similar GI50 values after single drug treatment. This indicates, that a similar level of 
cytotoxicity is needed for both compounds to maximize the synergistic effect. 
Supporting this notion, the lowest synergistic effect of all ALK fusion genes tested was 
observed in EML4-ALK v1 expressing cells, which showed the highest sensitivity 
towards HSP90 but only intermediate sensitivity to ALK inhibitor treatment (Figure 24, 
Table 2 page 61 ratio 2). To further increase synergistic effects, the respective drug 
concentrations might need to be adapted to the respective ALK fusion. In the case of 
EML4-ALK v1, crizotinib concentrations that are four- to five-fold higher than 17-DMAG 
drug concentrations might maximize the synergistic effect. That way, lower 
concentration of both drugs could be sufficient to induce cytotoxicity in these cells.  
In 2005, Radujkovic and colleagues published a study showing synergistic effects after 
treating BCR-ABL expressing cells with a combination of HSP90 and Abl inhibitors. 
These cells were resistant to treatment with the Abl inhibitor imatinib, but had no 
mutations in ABL. Interestingly, these cells showed a cross-resistance to HSP90 
inhibition, which was mediated by a high activity of the p-glycoprotein, an efflux pump 
with broad substrate specificity. Treatment with HSP90 inhibitors reduces protein levels 
of p-glycoprotein, thereby explaining the synergistic effect in these cells (Radujkovic et 
al., 2005). Point mutations in BCR-ABL that induced resistance to imatinib however did 
not alter the sensitivity to HSP90 inhibition, as has been shown for mutated EML4-ALK 
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(Gorre et al., 2002; Katayama et al., 2011; Sasaki et al., 2010a). Thus, point mutations 
that induce resistance to kinase inhibitors (typically located in close proximity to the 
ATP-binding pocket) do not seem to have a high impact on the protein stability in these 
fusion proteins. However, other proteins, like EGFR, have been shown to exhibit an 
increased sensitivity to HSP90 inhibition in a mutated status (Sawai et al., 2008). This 
effect has been explained by a shorter half-life of the mutated, and thereby constantly 
activated form of EGFR. In ALK fusion gene expressing cells however, no direct 
correlation between fusion protein turnover, kinase activity and HSP90 inhibitor 
sensitivity was observed. One possible explanation might be the intrinsic, coiled-coiled 
domain mediated, constant kinase activation that may attenuate any additional 
activation-induced destabilization. 
Unfortunately, no EML4-ALK variant 2 expressing human cell lines are available, to 
validate the described findings in a human cell line setting. The only commercially 
available EML4-ALK expressing cell lines are H3122 (variant 1) and H2228 (variants 
3a/b). However, it has been published that treatment of H2228 cells with ALK kinase 
inhibitors leads to a cytostatic effect, but does not induce apoptosis (Koivunen et al., 
2008). Thus, the H3122 cell line is the only available cell line responding with an 
“oncogene addiction” phenotype to ALK kinase inhibition, hampering the analysis of 
EML4-ALK variant specific cytotoxic effects in human cell line models. An artificial 
human cell line model could be generated by the overexpression of different EML4-ALK 
variants in H3122 cells, followed by silencing of the endogenous fusion gene. However, 
the ultimate prove that the observed differences in sensitivity translate into the clinic, 
can exclusively be shown in clinical trials.  
The single published crizotinib treated patient cohort consisted of only 31 variant 
annotated patients, and is thereby too small to confirm the described findings. In this 
study, only one confirmed EML4-ALK variant 2 positive patient was included, showing a 
tumor response rate of 57%. However, tumors expressing EML4-ALK v1 showed 
response rates from 33% - 100%, indicating that additional factors influenced the 
sensitivity of these tumors to crizotinib treatment (Kwak et al., 2010). Currently, ALK 
translocations in clinical trials are almost exclusively detected by FISH analysis (Kwak 
et al., 2010). By using ALK break-apart probes, ALK rearrangements are detected 
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without any information about the respective fusion partner or fusion variant. Thus, 
fusion variant specific responses cannot be analyzed. In order to enable specific variant 
calling, diagnostic tests that allow the exact identification of the expressed fusion variant 
need to be developed. One possibility would be an EML4-ALK fusion variant detection 
by RT-PCR, using RNA extracted from paraffin embedded tumor biopsies. However, 
this RNA is often degraded, allowing only the transcription of 100 - 150 bp long cDNA 
fragments. These fragments could then be used to run separate RT-PCRs, with a 
different forward primer (for each fusion variant) in each reaction. A better alternative 
would require fresh frozen biopsies for tumor RNA extraction, which, due to the 
generation of longer cDNA fragments, allow a multiplex RT-PCR approach for fusion 
variant detection (Takeuchi et al., 2008). Unfortunately, fresh frozen tumor biopsies are 
often difficult to obtain. In addition, in both RT-PCR approaches unknown fusions 
cannot be detected. RNA independent approaches would include parallel sequencing of 
the whole genome, or genomic regions of interest. However, these approaches are 
relatively expensive and need great expertise in the field of computational biology. 
Moreover, until now it is not completely clear if the different EML4-ALK variants arise on 
the genomic level or due to exon slippage. Hopefully, future clinical studies will analyze 
the specific ALK variant status and correlate these with tumor response rates. If 
different EML4-ALK variants induce variant specific response rates in the clinic, 
treatment schedules would need to be adapted accordingly.  
In addition to potential up-front resistance mechanisms (e.g. point mutations or, as 
shown in this study, different fusion variants), acquired resistance diminishes the clinical 
success of kinase inhibitors. Resistance mechanisms usually re-activate the signaling of 
the initial “driver mutation” by preventing the drug to bind to its target (in cis) or by 
substitution of the survival pathway initiator to another oncogene (in trans). Both of 
these mechanisms are often difficult to predict and, to take biological signaling circuits 
into account, can therefore only be analyzed in patients and cell culture or animal 
models. In fact, these approaches led to the discovery of several ALK kinase inhibitor 
resistance mutations in EML4-ALK expressing cells, hopefully accelerating the 
development of ALK inhibitors that are capable to inhibit these mutated kinases (Choi et 
al., 2010; Heuckmann et al., 2011; Katayama et al., 2011; Katayama et al., 2012; 
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Sasaki et al., 2011; Sasaki et al., 2010a; Zhang et al., 2011). Furthermore, previous 
studies on other kinase inhibitors have shown, that the identification of in-trans 
resistance mechanisms often allows the development of successful secondary 
treatment strategies (Emery et al., 2009; Johannessen et al., 2010; Nazarian et al., 
2010; Regales et al., 2009; Turke et al., 2010).  
In this study, several crizotinib resistance mutations were shown to be highly sensitive 
to ALK inhibition by the structurally diverse kinase inhibitor TAE684 (Figures 28 - 29) 
(Choi et al., 2010; Katayama et al., 2011; Sasaki et al., 2010a). Unfortunately, TAE684 
has not been developed for clinical use and therefore cannot be used to treat tumors 
harboring one of these mutations. Hopefully, ALK kinase inhibitors based on the 
scaffold of TAE684 will soon be available to treat of such tumors.  
The two described mutagenesis screens identified two novel resistance mutations, 
which induced a high level of resistance to PF02341066 and TAE684 (Figures 30 - 35). 
Structural modeling provided the mechanistic explanation for these findings, which are 
based on the binding mode of each inhibitor to the kinase. To overcome resistance of 
the L1198P mutation, a different target (e.g. HSP90) or a totally different binding mode, 
tolerating a highly activated kinase and avoiding the binding to the hinge region, would 
be needed. However, no allosteric ALK inhibitors have been described so far and it 
remains to be seen, if third-generation ALK inhibitors will be able to overcome 
resistance induced by the L1198P mutation (Milkiewicz and Ott, 2010).  
Recently, a study was published describing an ENU induced crizotinib resistance 
screen in EML4-ALK expressing Ba/F3 cells. Interestingly, as opposed to the data 
described here, the most prevalent mutations that were found in this study were 
L1196M, S1206R and G1269S/C, with no mutations at residue D1203 and only a small 
fraction of clones with L1198M mutations (Zhang et al., 2011). A possible explanation 
for the discrepancy between these two studies, are differences in the screening assay. 
As compared to the present study, Zhang and colleagues expressed EML4-ALK variant 
1 (not v3a) in Ba/F3 cells, incubated the ENU/crizotinib treated cells in 96-well plates for 
monoclonal resistant clones (no polyclonal culture and subsequent deep-sequencing) 
and treated the cells with crizotinib (not with the racemic mixture PF02341066). It would 
be interesting to see, if the EML4-ALK variant influences the development of specific 
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resistance mutations after ALK inhibitor treatment. Supporting this notion, all cases 
reporting the resistance mutation F1174L or L1196M allude to EML4-ALK variant 1 cell 
line models or primary tumor samples (Choi et al., 2010; Katayama et al., 2011; Sasaki 
et al., 2010a; Zhang et al., 2011). Furthermore, two recent studies analyzed crizotinib 
resistant tumors expressing EML4-ALK v3a and detected no F1174L or L1196M 
mutation (Doebele et al., 2012; Sasaki et al., 2011). An ALK inhibitor resistance screen 
in neuroblastoma cells, performed by Michael Hölzel at the NKI in the Netherlands, 
yielded as well the resistance mutation L1198P (Heuckmann et al., 2011). He 
performed a PCR-based mutagenesis screen for TAE684 resistance in the ALKF1174L 
expressing SH-SY5Y cell line and found the TAE684 resistance mutations G1123S, 
G1123D and L1198P. Interestingly, only the L1198P mutation induced resistance to 
PF02341066 (Heuckmann et al., 2011). The exact resistance mechanism of these 
G1123S/D mutations is currently unknown, however, these mutations are located in the 
glycine-rich loop of the kinase, which has been described to be crucial for ATP and 
ligand binding (Azam et al., 2003; Saraste et al., 1990). Furthermore, a study in thyroid 
cancer recently described one L1198F and one G1201E transforming mutation in ALK, 
however, no ALK kinase inhibitor sensitivity studies were performed (Murugan and Xing, 
2011). Thus, only five-years after the discovery of EML4-ALK translocations in lung 
cancer, a broad spectrum of ALK inhibitor resistance mutations has been described 
already. A similar spectrum of mutations has been shown to induce resistance to 
imatinib in BCR-ABL expressing cells (Azam et al., 2003; Shah et al., 2002). 
Interestingly, in EGFR mutated lung cancer, resistance to EGFR TKIs is almost 
exclusively mediated by the gatekeeper mutation (T790M) or in-trans resistance 
mechanisms, highlighting the influence of the kinase inhibitor binding-mode on the 
development of resistance mutations (Sequist et al., 2011; Sharma et al., 2007). 
In addition to resistance mutations within the ALK kinase domain, PF02341066 resistant 
H3122 cells showed an overexpression of the newly discovered SOS1-ADCY3 fusion 
protein, without any mutations in EML4-ALK (Figure 40, Figure 44). Previously, several 
publications have shown EGFR mutations and EML4-ALK amplifications as possible 
resistance mechanisms in EML4-ALK positive tumor cells (Doebele et al., 2012; 
Katayama et al., 2011; Koivunen et al., 2008; Sasaki et al., 2011). In the current study, 
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no differences in EGFR signaling and no overexpression of EML4-ALK were observed, 
with all SOS1-ADCY3 overexpressing cells showing an ALK inhibitor treatment 
independent activation of MAPK signaling. This finding is in line with the hypothesis, 
that resistance mechanisms usually re-activate the signaling pathway of the initial 
oncogene, which has been shown to be the MAPK pathway in H3122 cells (Katayama 
et al., 2011; Koivunen et al., 2008; Takezawa et al., 2011). NIH3T3 cells expressing the 
SOS1-ADCY3 fusion gene did not form colonies in soft agar, but formed tumors in a 
xenograft mouse model. The reason for this observation is currently unknown, with 
growth stimulating factors in the mouse serum or in the subcutaneous extracellular 
matrix being potential variables that stimulate the growth of these SOS1-ADCY3 
expressing cells only in mice. Another possible explanation might be the expression 
level of SOS1-ADCY3, with only high levels of fusion protein being capable to induce 
colony/tumor formation. Thus, only very few of the injected cells are able to form 
tumors, thereby explaining the delayed tumor formation that was observed in 
xenografts. However, both hypotheses need further analysis. In contrast to the SOS1-
ADCY3 overexpression, Katayama and colleagues identified EML4-ALK amplifications 
and the L1196M mutation in crizotinib resistant H3122 cells. To examine if the SOS1-
ADCY3 fusion is also present in the H3122 cells used in his study, Roopika Menon 
performed FISH analysis on these cells, confirming the existence of the genomic SOS1-
ADCY3 fusion. It is currently unknown, why some of these cells overexpress the SOS1-
ADCY3 fusion, and others develop the L1196M mutation as mechanism of ALK kinase 
inhibitor resistance.  
The current study highlights that the application of ALK inhibitors needs to take the 
exact genetic background (i.e. the exact fusion variant and potential resistance 
mutation) as well as the knowledge about compound activities for each resistance 
mutations into account. Some tumors with acquired (in-cis) crizotinib resistance 
mutations should respond to ALK kinase inhibitors of the diamino-pyrimidine scaffold, 
whereas other resistance mutation bearing tumors (e.g. L1198P and D1203N) should 
not respond to any type-I or type-II inhibitor. Conversely, if diamino-pyrimidine inhibitors 
are used for the treatment of EML4-ALK positive tumors, mutations in the glycine-rich 
loop of the kinase (G1123S/D) might develop, that can then be treated with crizotinib or 
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analogue drugs. However, all ALK fusion gene expressing tumors should be sensitive to 
HSP90 inhibition, independent of resistance mutation status (Katayama et al., 2011).  
In contrast to the development of new drugs, intermittent treatment with high doses of 
crizotinib might also be a possible treatment option. Several studies have shown that a 
relatively short duration of oncogene inhibition is sufficient to kill cancer cells (Hiwase et 
al., 2009; Shah et al., 2008; Snead et al., 2009). In such a scenario, high plasma levels 
of crizotinib could be achieved for a short period of time, which allow binding to the 
mutated kinase and subsequent induction of apoptosis in the tumor cell. However, it 
remains to be seen, if an intermittent treatment is sufficient to reduce the adverse 
effects that are provoked by sustained off-target inhibition (due to the high drug 
concentrations) to a tolerable level.  
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6 Summary 
EML4-ALK positive lung cancer can today effectively be treated with the ALK kinase 
inhibitor crizotinib. However, not only the initial tumor response to crizotinib treatment is 
heterogeneous, but also several resistance mutations that limit treatment efficiency 
have been described.  
In this study, cells expressing different EML4-ALK variants were shown to exhibit 
differential sensitivity to structurally unrelated ALK kinase inhibitors. Interestingly, these 
variants also exhibited differential HSP90 inhibitor sensitivity, however, with a varying 
distribution across the fusion variants. Furthermore, combining ALK and HSP90 
inhibitors induced synergistic cytotoxicity in all ALK fusion gene expressing cells, 
arguing for a functional link between HSP90 and the ALK fusion protein. Most likely, this 
functional interaction is based on the ALK fusion partner induced protein instability, 
which can be enhanced by kinase inhibitors, and attenuated by HSP90 binding. 
As opposed to these ALK inhibitor scaffold independent differences in sensitivity, cells 
expressing the crizotinib resistance mutations L1196M, F1174L or G1269S were highly 
sensitive to TAE684 treatment. Furthermore, two orthogonal mutagenesis screens 
identified two novel resistance mutations (L1198P and D1203N), which induced a high 
level of resistance to crizotinib and TAE684. The L1198P mutation most likely induced 
resistance to crizotinib by shifting the kinase equilibrium to a more active conformation 
and consequently hampering the inhibitor binding to the kinase domain. Resistance to 
TAE684 was most likely induced by mutation induced structural alterations at the hinge 
region of the kinase, impeding the interactions with the methoxy-group of TAE684. The 
exact mechanism of resistance induced by D1203N is unclear. Finally, the 
overexpression of a novel fusion protein in an EML4-ALK expressing cell line was 
described, which could induce ALK inhibitor resistance by MAPK pathway activation.  
The described mechanisms of differential sensitivity might explain some of the 
heterogeneous responses of EML4-ALK positive tumors after treatment with crizotinib. 
Furthermore, these findings demonstrate that the ALK genotype as well as the choice of 
ALK inhibitor highly impacts the therapeutic efficiency and should be taken into account 
for targeted therapy in ALK positive lung cancer and other cancers with ALK 
aberrations.   
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7 Outlook 
Lung cancer is one of the deadliest diseases of mankind. However, intensive research 
and technical advancement within the last 20 years allow a more optimistic view into the 
future. The decoding of several important biological processes that are essential for the 
survival of transformed cells enabled researchers to develop treatments that target 
these “Achilles heels” of tumor cells. Furthermore, future sequencing efforts will identify 
additional driver mutations in human tumors that will hopefully be targetable with dugs. 
The ability to sequence primary tumor samples and to identify genetic biomarkers for 
treatment decisions, today allows the use of targeted therapies only on those patients 
that are expected to respond. Such a combination of sequencing options and the 
biological understanding of tumor development improved the overall survival of many 
cancer patients already (Chapman et al., 2011; Druker et al., 2001; Kwak et al., 2010; 
Mok et al., 2009). Even though these examples are a huge success in the fight against 
cancer, the genetic drivers of many tumors are not yet known or cannot be targeted 
today.  
However, researchers can make use of a broad spectrum of functional analyses to 
dissect the biology behind a tumor cell. This study showed once again, that the exact 
knowledge about the genetic event leading to a certain phenotype, allows an adaptation 
(i.e. different drug) of treatment. In addition, a general understanding of the biochemical 
protein characteristics was shown to allow an enhancement in treatment efficiency (i.e. 
drug combinations). The current knowledge about possible resistance mechanisms in 
ALK already allows the development of second- or third-generation kinase inhibitors, 
which circumvent the respective resistance mechanism by a different binding mode. 
Hopefully, such improved drugs will soon be available and will translate the pre-clinical 
treatment success into the clinic.  
Nevertheless, the question remains, if constant adaptations and improvements of 
cancer care will eventually allow the cure of cancer, or if adaptations in cancer 
treatment will always initiate the development of novel resistance mechanisms. The 
latter could be compared to current efforts to contain resistance in viral infections, with 
virus particles constantly evolving to escape the available treatment. In such a scenario, 
permanent adaptations in cancer treatment could make cancer become a chronic 
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disease, with an increase in overall survival, but no cure. A more unfavorable scenario 
would be, that tumor cells shift their oncogenic signaling to proteins that cannot be 
targeted, or switch to signaling pathways that are also essential for the survival of non-
transformed cells. However, in that case, a careful analysis of potential therapeutic 
windows for available drugs still might allow the treatment of these tumors.  
Hopefully, future scientific advances will not only enhance current techniques (whole 
genome sequencing, kinase inhibitors etc.), but also allow the development of 
completely new treatment strategies to address the great demand for effective cancer 
treatment. 
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